<PAGE>
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[X] Preliminary Proxy Statement [_] CONFIDENTIAL, FOR USE OF THE
COMMISSION ONLY (AS PERMITTED BY
[_] Definitive Proxy Statement RULE 14A-6(E)(2))
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to (S)240.14a-11(c) or (S)240.14a-12
OXIS INTERNATIONAL, INC.
------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
--Enter Company Name Here--
------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2) or
Item 22(a)(2) of Schedule 14A.
[_] $500 per each party to the controversy pursuant to Exchange Act Rule
14a-6(i)(3).
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
Notes:
<PAGE>
OXIS INTERNATIONAL, INC.
6040 N. Cutter Circle, Suite 317
Portland, Oregon 97217
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
June 13, 1996
NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of OXIS
International, Inc., a Delaware corporation ("OXIS" or the "Company"), will be
held at the Hotel Vintage Plaza, 627 S.W. Washington Street, Portland, Oregon
97205, on Thursday, June 13, 1996 at 2:00 p.m. (local time), for the following
purposes:
1. To elect a Board of eight (8) Directors to serve for the ensuing year
and until their successors are elected.
2. To consider and act upon a proposal to amend the Company's Restated
Certificate of Incorporation to (i) increase the authorized number of
shares of OXIS common stock from 25,000,000 shares to 40,000,000
shares and (ii) increase the authorized number of shares of OXIS
preferred stock from 5,000,000 shares to 15,000,000 shares. YOU MUST
VOTE "FOR" OR "AGAINST" OR ABSTAIN FROM VOTING ON THIS PROPOSAL AS A
WHOLE. YOU MAY NOT VOTE "FOR" THE INCREASE IN AUTHORIZED COMMON STOCK
BUT "AGAINST" THE INCREASE IN AUTHORIZED PREFERRED STOCK AND VICE
VERSA.
3. To approve an amendment of the Company's 1994 Stock Incentive Plan to
increase the number of shares of common stock available for issuance
thereunder by 1,000,000 shares, to an aggregate of 2,200,000 shares.
4. To transact such other and further business as may properly come
before the meeting or adjournment or adjournments thereof.
Common and preferred stockholders of record at the close of business on
April 19, 1996, are entitled to notice of and to vote at the meeting. A
complete list of such stockholders is open to examination of any stockholder
for any purpose germane to the meeting, during ordinary business hours, at the
offices of the Company, located at 6040 N. Cutter Circle, Suite 317, Portland,
Oregon 97217.
A copy of the Company's Annual Report for the fiscal year ended December
31, 1995, is enclosed herewith.
By Order of the Board of Directors
Jon S. Pitcher, Secretary
Dated: April 26, 1996
You are urged to fill in, sign, date and mail the enclosed Proxy as soon as
possible. If you attend the meeting and vote in person, the Proxy will not be
used. If the Proxy is mailed in the United States in the enclosed envelope, no
postage is required. The prompt return of your Proxy will save the expense
involved in further communication.
<PAGE>
OXIS INTERNATIONAL, INC.
6040 N. Cutter Circle, Suite 317
Portland, Oregon 97217
PROXY STATEMENT
for Annual Meeting of Stockholders
to be held on June 13, 1996
April 26, 1996
This Proxy Statement is furnished to you in connection with the solicitation by
the Board of Directors of OXIS International, Inc., a Delaware corporation (the
"Company"), of proxies in the accompanying form to be used at the Annual Meeting
of Stockholders to be held at the Hotel Vintage Plaza, 627 S.W. Washington
Street, Portland, Oregon 97205, on Thursday, June 13, 1996 at 2:00 p.m. (local
time) and at any subsequent time which may be necessary by the adjournment
thereof.
If you were a holder of record of common stock, Series B Preferred Stock or
Series C Preferred Stock of the Company (the "Voting Stock") at the close of
business on April 19, 1996, you are entitled to vote at the meeting and your
presence is desired. However, to assure your representation at the meeting, you
are urged by the Board of Directors of the Company to sign and return the
enclosed proxy as soon as possible. You can, of course, revoke your proxy at
any time before it is voted if you so desire, either in person at the meeting or
by delivery of a duly executed written statement to that effect to the Secretary
of the Company.
The Company is paying all costs of the solicitation of proxies, including the
expenses of printing and mailing to its stockholders this Proxy Statement, the
accompanying Notice of Annual Meeting of Stockholders and form of Proxy and the
Annual Report to Shareholders for the fiscal year ended December 31, 1995. The
Company has engaged D.F. King & Co. to assist the Company in the distribution
and solicitation of Proxies and has agreed to pay D.F. King & Co. a fee of $750
plus expenses for its services. The Company will also reimburse brokerage
houses and other custodians, nominees and fiduciaries for their expenses, in
accordance with the regulations of the Securities and Exchange Commission, in
sending proxies and proxy materials to the beneficial owners of the Company's
common stock. Officers or employees of the Company may also solicit proxies in
person, or by mail, telegram or telephone, but such persons will receive no
compensation for such work, other than their normal compensation as such
officers or employees.
At the close of business on April 19, 1996, 12,124,423 shares of common stock,
642,583 shares of Series B Preferred Stock, and 663,976 shares of Series C
Preferred Stock were outstanding and are entitled to vote at the Annual Meeting.
Each share of common stock and Series B Preferred Stock outstanding as of the
April 19, 1996 record date is entitled to one vote. Each share of Series C
Preferred Stock outstanding as of April 19, 1996 is entitled to the number of
votes equal to 1.30 divided by the average closing bid price of the Company's
common stock during the fifteen (15) consecutive trading days immediately
prior to the date such share of Series C Preferred Stock was purchased. As of
the record date, each share of Series C Preferred Stock would be entitled to
1.29 - 1.35 votes, resulting in a total of 883,221 votes for all of the
Series C Preferred Stock outstanding. This Proxy Statement and the enclosed
Proxy are first being mailed to the stockholders of the Company on or about
April 30, 1996.
PROPOSALS OF STOCKHOLDERS
Proposals of stockholders intended to be presented at the 1997 Annual Meeting of
Stockholders must be received at the Company's executive offices on or before
January 15, 1997, for inclusion in the Company's Proxy Statement with respect
to such meeting.
<PAGE>
PROXIES AND VOTE REQUIRED
Proxies
The persons named as Proxies for the OXIS Meeting in the enclosed proxy card
(Ray R. Rogers, director and Chairman of the Board and Anna D. Barker, Ph.D.,
director and President and Chief Executive Officer) were selected by OXIS' Board
of Directors.
Voting of Proxies
All properly executed proxies that are not revoked will be voted at the OXIS
Meeting in accordance with the instructions contained therein. Proxies
containing no instructions regarding the proposals specified in the form of
proxy will be voted FOR approval of all proposals in accordance with the
recommendation of the Board of Directors of the Company. Any stockholder
signing a proxy has the power to revoke it prior to the OXIS meeting, or at the
meeting, prior to the vote pursuant to the proxy. A proxy may be revoked by
delivering a written notice of revocation or a duly executed proxy bearing a
later date or by attending the OXIS Meeting and voting in person.
Vote Required
Under Delaware law, approval of the amendment of OXIS' Restated Certificate of
Incorporation to increase the authorized number of shares of preferred and
common stock requires the affirmative vote of the holders of the majority of the
outstanding shares of OXIS common stock and preferred stock entitled to vote and
abstentions will be treated as votes against. Approval of the proposal to adopt
the amendment to 1994 Stock Incentive Plan requires the affirmative vote of the
majority of shares of OXIS stock entitled to vote and present in person or
represented by proxy and abstentions will be treated as votes against. The
election of directors requires a plurality of the votes of the shares present in
person or represented by proxy and entitled to vote thereon. If a quorum is
present those nominees receiving a plurality of the votes cast will be elected.
Accordingly, shares not voted in the election of directors (including shares
covered by a proxy as to which authority is withheld to vote for all nominees)
and shares not voted for any particular nominee (including shares covered by a
proxy as to which authority is withheld to vote for only one or less than all of
the identified nominees) will not prevent the election of any of the nominees
for director. For any other matter submitted to stockholders at the meeting, if
a quorum is present the affirmative vote of the majority of the shares voted is
required for approval. As a result, abstention votes have the effect of a vote
against such matters.
The presence in person or by proxy of a majority of the shares of common stock
outstanding and entitled to vote at the meeting is required for a quorum.
Effect of Broker Non-Votes
"Broker Non-Votes" occur when a broker holding shares of stock in street name
withholds his vote on certain non-routine matters because the broker has not
received instructions from the beneficial owner of those shares of stock and
does not have discretionary authority to vote on such non-routine matters
without such instructions. Under the Rules of the National Association of
Securities Dealers, Inc., brokers holding shares of stock in street name must
receive specific instructions from the beneficial owners in order to have the
authority to vote, in person or by proxy, on certain "non-routine" matters as
defined under those Rules. When a beneficial owner does not give specific
instructions to the broker, the broker, as the holder of record, is entitled to
vote only on "routine" matters and must withhold its votes as to any non-routine
matters. When a proxy solicitation includes a non-routine proposal and the
broker does not receive specific instructions from the beneficial owner, the
resulting proxy is considered a "limited proxy". Shares represented by limited
proxies are considered present for quorum purposes. However, shares represented
by limited proxies are not considered present for purposes of determining the
total number of shares with voting power present with regard to a non-routine
proposal. The resulting broker non-vote will not be counted for or against such
non-routine proposal.
2
<PAGE>
Proposal 3 (Approval of the OXIS 1994 Stock Incentive Plan) is a "non-routine"
proposal. Shares represented by limited proxies are not considered present for
purposes of determining the total number of shares with voting power present
with regard to this proposal. (Broker non-votes will not be counted for or
against this proposal). Proposal 2 (Amendment to the Restated Certificate of
Incorporation) is also a "non-routine" proposal. However, the amendment to the
Restated Certificate of Incorporation requires the affirmative vote of a
majority of the outstanding stock entitled to vote thereon. Thus, all shares
represented by a limited proxy at the meeting, even if unauthorized to vote for
or against the Amendment to the Restated Certificate of Incorporation would be
included. Broker non-votes will therefore be counted in the total pool of votes
respecting Proposal 2. The ultimate effect will be that broker non-votes will
have the same effect as votes against Proposal 2. Proposal 1 (Election of
Directors) is a "routine" matter upon which brokers can cast votes with or
without specific instructions from the beneficial holders and are thus counted
for purposes of determining whether such Proposal has been approved.
PROPOSAL NO. 1 -- ELECTION OF DIRECTORS
(Item 1 on Proxy Card)
The Board of Directors of the Company currently consists of eight individuals,
all of whom have been nominated for election at the meeting. Unless otherwise
instructed, the proxy holders will vote the proxies held by them for the
Company's eight nominees. In the event that any such nominee is unable or
declines to accept nomination or election, the proxies will be voted for any
nominee who shall be recommended by the present Board of Directors. Directors
are to be elected to hold office until the next Annual Meeting of Stockholders
or until their respective successors shall have been elected and qualified. The
names and ages of the eight nominees for director are set forth below:
<TABLE>
<CAPTION>
Name Age Position
------------------------ --- -----------------------------------------------
<S> <C> <C>
Ray R. Rogers 56 Director, Chairman of the Board
Anna D. Barker, Ph.D. 56 Director, President and Chief Executive Officer
Timothy G. Biro 42 Director
Stuart S. Lang 59 Director
James D. McCamant 62 Director
Gerald D. Mayer, Ph.D. 63 Director
David A. Needham, Ph.D. 57 Director
A.R. Sitaraman 62 Director
</TABLE>
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ELECTION OF THE NOMINEES
LISTED ABOVE TO THE COMPANY'S BOARD OF DIRECTORS.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Beneficial Ownership of Securities
Common Stock
The following table sets forth certain information, as of March 31, 1996, with
respect to persons known to the Company to be the beneficial owner of more than
five percent of the Company's common stock and beneficial ownership by directors
and executive officers of the Company's common stock. Executive officers not
required to be included in the Summary Compensation Table are not shown
individually, but are included in the line captioned "Executive officers and
directors as a group -- 10 persons".
3
<PAGE>
<TABLE>
<CAPTION>
Name and, as Amount and nature Percent of
appropriate, address of beneficial ownership class/1/
- -------------------- ----------------------- ----------
<S> <C> <C>
Brantley Venture Partners II, L.P.
20600 Chagrin Blvd., Suite 1150
Cleveland, OH 44122 764,893/9/ 6.20%
S.R. One Limited
565 E. Swedesford Road, Suite 315
Wayne, PA 19087 977,886/9/ 7.79%
Dr. Anna D. Barker 951,472/2//3/ 7.80%
Timothy G. Biro 20,000/2//10/ *
Stuart S. Lang 17,000/2/ *
Dr. Gerald D. Mayer 22,500/2//4/ *
James D. McCamant 135,000/2//5/ 1.11%
Dr. David A. Needham 20,000/2//6/ *
Jon S. Pitcher 54,084/2/ *
Ray R. Rogers 700,701/2//7/ 5.74%
A.R. Sitaraman 71,700/2//8/ *
Executive officers and directors
as a group -- 10 persons 1,992,457 16.04%
</TABLE>
* Less than one percent.
/1/ As required by regulations of the Securities and Exchange Commission, the
number of shares in the table includes shares which can be purchased within
60 days. Also required by such regulations, each percentage reported in
the table for these individuals is calculated as though shares which can be
purchased within 60 days have been purchased by the respective person or
group and are outstanding.
/2/ The holdings of directors Lang and McCamant each include 15,000 shares
subject to options. The holdings of directors Biro, Mayer, Needham and
Sitaraman each include 20,000 shares subject to options. The holdings of
Anna D. Barker include 73,333 shares subject to options. The holdings of
Jon S. Pitcher include 32,459 shares subject to options. The holdings of
Ray R. Rogers include 78,333 shares subject to options.
/3/ Dr. Barker's holdings include 401,285 shares owned by Dr. Barker jointly
with her spouse.
/4/ 2,000 of these shares are owned by Dr. Mayer jointly with his spouse, and
500 shares are owned by Dr. Mayer's individual retirement account.
/5/ Included are 120,000 shares owned by America HealthCare Fund, L.P., a
limited partnership of which Mr. McCamant is the sole general partner. Mr.
McCamant also owns 85% of Piedmont Venture Group, which is a major investor
in America HealthCare Fund, L.P.
/6/ Dr. Needham is a consultant to the investment advisory firm which advises
Alta-Berkeley L.P. II. Dr. Needham disclaims beneficial ownership of
534,322 shares owned by Alta-Berkeley L.P. II and 16,452 shares subject to
options held by Alta-Berkeley L.P. II.
/7/ Included are 10,000 shares owned by his individual retirement account, as
to which Mr. Rogers exercises voting and investment power. Excluded from
Mr. Rogers' shares are 140,771 shares owned by an irrevocable trust for the
benefit of his children.
/8/ Mr. Sitaraman's holdings include 15,300 shares owned by his SEP-IRA, 8,700
shares owned by his wife's SEP-IRA, 6,000 shares owned in equal amounts by
Mr. Sitaraman's and his spouse's individual retirement accounts, 11,700
shares owned jointly with his spouse and 10,000 shares held by his
daughter, as to which shares Mr. Sitaraman disclaims beneficial ownership.
4
<PAGE>
/9/ The holdings of Brantley Venture Partners II, L.P. include 214,194 shares
of the Company's Series B Preferred Stock, which are convertible into an
equal number of shares of common stock. The holdings of S.R. One, Limited
include 428,389 shares of the Company's Series B Preferred Stock which are
convertible into an equal number of shares of common stock.
/10/ Mr. Biro is a general partner of Brantley Venture Partners II, L.P.
("Brantley"). Pursuant to transactions which closed on July 19, 1995,
Brantley owns 550,699 shares of common stock and 214,194 shares of the
Company's Series B Preferred Stock. Mr. Biro disclaims beneficial
ownership of shares held by Brantley.
Series B Preferred Stock
The following table sets forth certain information, as of March 31, 1996, with
respect to persons known to the Company to be the beneficial owner of more than
five percent of the Company's Series B Preferred Stock.
<TABLE>
<CAPTION>
Amount and nature Percent of
Name and address of beneficial ownership class
---------------- ----------------------- ----------
<S> <C> <C>
Brantley Venture Partners II, L.P.
20600 Chagrin Blvd., Suite 1150
Cleveland, OH 44122 214,194 33.33%
S.R. One Limited
565 E. Swedesford Road, Suite 315
Wayne, PA 19087 428,389 66.67%
</TABLE>
Series C Preferred Stock
The following table sets forth certain information, as of March 31, 1996, with
respect to persons known to the Company to be the beneficial owner of more than
five percent of the Company's Series C Preferred Stock.
<TABLE>
<CAPTION>
Amount and nature Percent of
Name and address of beneficial ownership class
---------------- ----------------------- ----------
<S> <C> <C>
Rauch & Co.
c/o State Street Bank & Trust
225 Franklin Street
Boston, MA 02110 200,000 30.12%
Legong Investments N.V.
International Trade Center TM 126
P.O. Box 6050 Piscadera Bay
Curacao, Netherlands Antilles 153,846 23.17%
Marc Dumont
37 Chemin Jean Achard
CH-1231 Conches Geneve Switzerland 76,977 11.59%
D.N.B. Fund Partners, L.P.
3540 Pierce Street
San Francisco, CA 94123 76,977 11.59%
Gestor Finance S.A.
42, ave. de la Grand Armee
75017 Paris France 50,000 7.53%
</TABLE>
5
<PAGE>
<TABLE>
<CAPTION>
Amount and nature Percent of
Name and address of beneficial ownership class
---------------- ----------------------- ----------
<S> <C> <C>
Marc Rebagliati
45, Quai Wilson C.P. 365
1211 Geneve Switzerland 46,000 6.93%
</TABLE>
Certain Relationships and Related Transactions
Brantley Venture Partners II, L.P. and S.R. One Limited, which each hold in
excess of five percent of the Company's common stock and which together own 100%
of the Company's Series B Preferred Stock, were major shareholders of Therox
Pharmaceuticals, Inc., prior to its merger with a subsidiary of the Company in
July 1995. Brantley Venture Partners II, L.P. received 550,699 shares of common
stock in exchange for its shares of Therox Pharmaceuticals, Inc., and S.R. One
Limited received 549,497 shares of common stock in exchange for its shares of
Therox Pharmaceuticals, Inc.
Simultaneously with the acquisition of Therox Pharmaceuticals, Inc., the Company
sold 214,195 shares of its Series B Preferred Stock to Brantley Venture Partners
II, L.P. for $500,000 and 428,389 shares of its Series B Preferred Stock to S.R.
One Limited for $1,000,000.
The holders of Series C Preferred Stock listed in the table above purchased
their shares from the Company in January and February 1996 at a price of $1.30
per share.
The Company has paid, or accrued to pay, $68,545 in cash for legal and
consulting services during 1995 by Mr. Taussig, a director of the Company until
December 31, 1995. In addition, in March 1996, the Company's Compensation
Committee awarded Mr. Taussig a grant of 35,000 shares of common stock and an
option to purchase an additional 35,000 shares of common stock as part of his
compensation for services rendered during 1995.
DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY
Set forth below is information regarding the directors and executive officers of
the Company.
Anna D. Barker, Ph.D.
Age: 56
Dr. Barker has been a director of the Company since May 10, 1993, and also
previously served as the President and Chief Executive Officer of International
BioClinical, Inc. ("IBC") from 1992 until its merger with OXIS in 1994. She
became President and Chief Executive Officer of OXIS on September 7, 1994. Dr.
Barker has over 20 years of senior international management experience with
Battelle Memorial Institute ("Battelle") in the development and leadership of
research and development and technology-based businesses, specifically:
biotechnology; toxicology/pharmacology; analytical chemistry; and regulatory-
based support for the drug development process. After leaving Battelle in 1991,
Dr. Barker performed consulting services on an independent basis prior to
joining IBC in 1992.
Dr. Barker serves on numerous committees and boards for both scientific
societies and The National Institutes of Health. She has also published several
scientific papers in the area of tumor immunology and received a number of
awards from national agencies and civic organizations for her professional
achievements and civic activities. She holds B.S. and M.S. degrees from
Morehead State University and Ohio State University, respectively. Dr. Barker
received her Ph.D. degree in Microbiology from Ohio State University in 1971.
Timothy G. Biro
Age 42
Mr. Biro has been a director of the Company since August 15, 1995. Mr. Biro is a
general partner of Brantley Ventures Partners II, L.P. and Brantley Venture
Partners III, L.P. In addition to being a director of OXIS, Mr. Biro is a
member of the boards of directors of several privately held companies in which
Brantley Venture Partners has invested.
6
<PAGE>
Prior to joining Brantley Venture Partners in 1991, Mr. Biro was Superintendent
of Pharmaceutical Manufacturing at Merck & Co., Inc. Mr. Biro holds B.S.
degrees in Microbiology from Pennsylvania State University and in Pharmacy from
Temple University, and an MBA from the Wharton School of Business.
Stuart S. Lang
Age 59
Mr. Lang was elected to the board on January 19, 1996, to fill a vacancy.
Mr. Lang has worked in the accounting field for over 25 years. He has been a
tax partner and subsequently partner in charge of the Portland office of a
national CPA firm. He founded a local accounting firm in Portland, Oregon, in
1985, and is managing member of that firm.
During his career, Mr. Lang has specialized in a variety of areas, including
mergers, sales and acquisitions, strategic business planning, business valuation
and patents and copyrights. He serves litigation clients in the areas of
accountant's professional liability, business valuations, and the application of
generally accepted accounting principles and auditing standards. He is a
frequent expert witness in the field of forensic accounting.
Mr. Lang is past Chairman of IA International. He has served as a member of
AICPA tax subcommittees, including Responsibilities in Tax Practice, and as
chairman of the OSCPA Taxation and Estate Planning Committees.
James D. McCamant
Age 62
Mr. McCamant was elected to the board on January 19, 1996, to fill a vacancy.
Mr. McCamant is the editor of the Medical Technology Stock Letter and the
AgBiotech Stock Letter. He has held those positions since the founding of those
newsletters in December 1983 and August 1988 respectively. In addition, Mr.
McCamant is the President of Piedmont Venture Group, the publisher of the two
letters.
Mr. McCamant is the general partner of American Health Care Fund, LP, an
investment partnership with a focus on investing in biotechnology stocks. From
1960 until he began the investment letter business, Mr. McCamant worked as a
broker, analyst and principal for a number of brokerage firms in Northern
California.
Gerald D. Mayer, Ph.D.
Age: 63
Dr. Mayer has been a director of the Company since May 10, 1993. Dr. Mayer
retired at the end of 1992 as Director of Clinical Microbiology for the Anti-
Infective Division of Marion Merrell Dow, Inc., after 27 years with that
pharmaceutical manufacturer and its predecessors.
From 1978 to 1991, Dr. Mayer also held an adjunct faculty position at the
University of Cincinnati Medical School's Department of Biochemistry, Molecular
Genetics and Microbiology. Dr. Mayer's particular research interests include
interferon inducers, interferons, antivirals and antibiotics. He has presented
or published more than 45 articles in peer review journals in the microbiology
field. In addition, he has served as an observer to the National Committee of
Clinical Laboratory Standards.
Dr. Mayer received his B.S. degree in General Sciences (Chemistry) in 1958 from
the University of Southwestern Louisiana. He received his Master's degree in
1960 in Microbiology from the same institution. In 1964, Dr. Mayer received his
Ph.D. in Microbiology from Iowa State University.
7
<PAGE>
David A. Needham, Ph.D.
Age: 57
Dr. Needham has been a director of OXIS since September 16, 1994. He is a
consultant with Alta-Berkeley Associates, London, England, a venture capital
group that invests in healthcare, including biotechnology, media and information
services businesses. Dr. Needham has worked with Alta-Berkeley since 1985 and
is a director of several private companies in which Alta-Berkeley has invested.
Prior to joining Alta-Berkeley in 1985, Dr. Needham worked in the United States.
Beginning in 1981, he worked for BOC Healthcare where he was responsible for
strategic direction and integration of worldwide operations and acquisition of
new technology. Previously, Dr. Needham was a Divisional Director of the
Medishield Corporation, responsible for a number of critical care equipment
businesses supplying international markets. Prior to 1976 he was the Managing
Director of a venture-backed United Kingdom medical equipment company. Dr.
Needham is a graduate of Imperial College, University of London with B.Sc. Hons,
and a Ph.D. in Aeronautical Engineering.
Ray R. Rogers
Age: 56
Mr. Rogers has been Chairman of the Board of the Company since May 10, 1993. He
also served as Chairman of the Board of Directors of IBC from its organization
in 1983 until its merger with the Company in 1994. Mr. Rogers served as
President and Chief Executive Officer of IBC from 1983 until 1992 when he
recruited Dr. Barker to serve those roles.
Prior to his involvement with IBC, Mr. Rogers was the principal in charge of
consulting services at the Portland, Oregon, office of the international
accounting firm of Arthur Young & Company. Mr. Rogers received his B.S. degree
in Business Administration in 1964 from California State University, Chico.
A.R. Sitaraman
Age: 62
Mr. Sitaraman has been a director of the Company since May 10, 1993. Mr.
Sitaraman earned an industrial engineering degree prior to graduating from the
Indian Air Force Flying College and embarking upon an 18-year career as a pilot
and instructor in the Indian Air Force. In 1974, Mr. Sitaraman entered the
property management business in the United States. Mr. Sitaraman was a National
Advisory Council Member of the National Center for Housing Management from its
inception in 1976 through the end of 1990. Mr. Sitaraman was awarded "Certified
Property Manager" designation by the Institute of Real Estate Management in
1985.
Mr. Sitaraman is the President and Chief Executive Officer of Sitrex
International, Inc., a corporation involved in development, syndication and
consulting in the real estate industry, in addition to the import and export
business. Mr. Sitaraman has also specialized in corporate turn-arounds
involving large real estate corporations having real estate assets of over a
billion dollars.
Jon S. Pitcher
Age: 46
Mr. Pitcher, a Certified Public Accountant, has been Vice President and Chief
Financial Officer of OXIS since September 7, 1994, and Secretary of the Company
since August 15, 1995. Prior to the merger of International BioClinical, Inc.
with the Company, Mr. Pitcher was Chief Financial Officer of International
BioClinical, Inc., a position he had held since 1991.
8
<PAGE>
Prior to joining International BioClinical, Inc., Mr. Pitcher was a partner in
the international accounting firm, Ernst & Young, specializing in services to
health care clients. Mr. Pitcher joined Arthur Young & Company in 1973 and
became a partner in that firm in 1987. He became a partner in Ernst & Young
when Arthur Young & Company merged into Ernst & Young. Mr. Pitcher received his
B.S. degree in Business Administration from Pepperdine University in 1971 and
his M.S. degree in Management from UCLA in 1973.
Timothy C. Rodell, M.D.
Age: 45
Dr. Rodell has been Chief Operating Officer of the Company since March 1, 1996.
Prior to joining OXIS, Dr. Rodell spent ten years with Cortech, Inc., where he
was most recently Executive Vice President of Operations and Product
Development. At Cortech, Dr. Rodell was responsible for all phases of drug
development including regulatory affairs and clinical trials.
Dr. Rodell received his M.D. and A.B. degrees from the University of North
Carolina, at Chapel Hill. He subsequently completed post-doctoral training at
the Eleanor Roosevelt Institute for Cancer Research and the Webb-Waring Lung
Institute in Denver, Colorado. Dr. Rodell is Board Certified in Internal
Medicine and Pulmonary Medicine and is a Fellow of the American College of Chest
Physicians. He is currently a Clinical Assistant Professor of Medicine at the
University of Colorado Health Sciences Center.
BOARD AND COMMITTEE MEETINGS
The Board of Directors has a Compensation Committee, whose function is to
administer the Company's 1994 Stock Incentive Plan and other compensation plans
and to act upon such other compensation matters as may be referred to it by the
Board. The members of the Committee during 1995 were Messrs. Brown and Taussig.
The Compensation Committee met 4 times during 1995 with both members in
attendance at each meeting.
The Board has an Audit Committee which oversees the Company's internal
accounting procedures and consults with, and reviews the reports of, the
Company's independent accountants. The members of the Committee during 1995
were Messrs. Brown and Taussig. The Audit Committee met 5 times during 1995
with both members in attendance at each meeting.
Effective December 31, 1995, Messrs. Brown and Taussig both resigned from the
Board of Directors. In January 1996 the Board of Directors appointed Stuart S.
Lang and James D. McCamant as directors to serve until the next annual meeting
of the Company. In January 1996 the board also appointed Messrs. Biro, Lang and
Sitaraman to serve as members of the Company's Compensation and Audit
Committees.
During the year ended December 31, 1995, the Board of Directors of the Company
met ten times and each director attended at least 75% of the Company's Board
meetings. The Board does not have a separate nominating committee.
COMPENSATION OF EXECUTIVE OFFICERS
Directors
The Company pays an annual fee of $4,000 to each non-employee director and an
additional $1,000 to non-employee directors for serving as committee chairmen,
but does not pay meeting fees. Directors are also reimbursed for their expenses
incurred in attending meetings. Employee directors receive no compensation as
directors. Compensation is also paid for special assignments. The Company has
paid, or accrued to be paid, $68,545 in cash for legal and consulting services
by Mr. Taussig during 1995. In addition, in March 1996, the
9
<PAGE>
Compensation Committee awarded Mr. Taussig a grant of 35,000 shares of common
stock and an option to purchase an additional 35,000 shares of common stock as
part of his compensation for services rendered during 1995.
Under the Company's 1994 Stock Incentive Plan non-employee directors are awarded
options to purchase 15,000 shares of common stock upon becoming directors of the
Company and options to purchase 5,000 shares of common stock annually
thereafter.
Executive Officers
Summary Compensation Table
The following table shows the compensation paid during the last three years to
Company officers who received more than $100,000, or served as Chief Executive
Officer during 1995:
<TABLE>
<CAPTION>
Long Term
Compensation
------------
Annual Compensation Awards
--------------------- ------------
Name and Position Year Salary Bonus Options
<S> <C> <C> <C> <C>
Ray R. Rogers,
Chairman, President and CEO 1995 $185,000 $42,000/6/ 55,000/5/
(from May 10, 1993 to September 7, 1994) 1994 $153,125 $31,500/3/ 30,000/4/
Chairman of the Board 1993 $ 83,570 $15,000/1/
(from September 7, 1994)
Anna D. Barker,
President and Chief Executive Officer 1995 $185,000 $42,000/6/ 55,000/5/
(from September 7, 1994) 1994 $ 58,163 $10,500/3/ 25,000/2/
Jon S. Pitcher
Vice President, Chief Financial Officer
and Secretary 1995 $ 91,333 $10,500/6/ 25,000/5/
</TABLE>
- -------------------
/1/ Accrued in 1993 and paid in 1994.
/2/ Options to purchase 15,000 shares of the Company's common stock at an
exercise price of $3.50 per share awarded to Dr. Barker as a non-employee
director before she became an employee of the Company, and options to
purchase 10,000 shares of the Company's common stock awarded as part of her
1994 compensation.
/3/ Bonuses for 1994 awarded by the Company's board of directors.
/4/ Options to purchase 30,000 shares of the Company's common stock awarded
to Mr. Rogers as part of his 1994 compensation.
/5/ Options to purchase 55,000 shares each awarded to Mr. Rogers and Dr.
Barker and options to purchase 25,000 shares awarded to Mr. Pitcher as part
of their 1995 compensation.
/6/ Bonuses for 1995 of which $27,000 each for Mr. Rogers and Dr. Barker
and $10,500 for Mr. Pitcher were approved by the Compensation Committee in
March 1996.
Stock Purchase Warrants
In prior years, the Company issued warrants to purchase shares of common stock
to certain officers and key employees (none of whom any longer hold a position
with the Company) and to former directors.
Upon exercise of a warrant, the purchase price for the number of shares being
purchased is payable in cash. Warrants contain provisions for adjustments in
the event of stock splits, stock dividends, reorganizations and similar events.
Warrants are taxed as stock options which do not meet the requirements of the
Internal Revenue Code of 1986 for incentive stock options. As a consequence,
warrants do not receive the favorable tax treatment accorded to
10
<PAGE>
incentive stock options. Generally, upon exercise or transfer of a warrant, the
holder of the warrant realizes ordinary taxable income, and the Company realizes
a tax deduction, equal to the difference between the exercise price and the fair
market value of the shares at the time, without regard to legal restrictions on
transfer of the shares in the event the shares received are not registered
pursuant to the Securities Act. To avoid the necessity for the warrant holder to
borrow cash to purchase the shares subject to a warrant, exercisable warrants
are subject to registration by the Company pursuant to the Securities Act and
the warrants and underlying shares are transferable.
All warrants issued to former officers, directors and key employees are
exercisable at $2.875 per share and expire through December 31, 1999.
Stock Options
The Company has reserved 1,200,000 shares of common stock for issuance under the
1994 Stock Incentive Plan. The plan permits granting stock options to acquire
shares of the Company's common stock, awarding stock bonuses of the Company's
common stock, and granting stock appreciation rights. As of December 31, 1995,
options to purchase 382,900 shares of the Company's common stock had been issued
and were outstanding under this plan. During 1994, options to purchase 15,000
shares of the Company's common stock at an exercise price of $3.50 per share
were granted to directors Barker, Brown, Mayer, Sitaraman and Taussig; and
options to purchase 15,000 shares of the Company's common stock at an exercise
price of $3.13 were granted to Dr. Needham. During 1995, options to purchase
the following shares of the Company's common stock were issued to directors:
25,000 to Dr. Barker and 45,000 to Mr. Rogers at an exercise price of $3.50;
20,000 to Mr. Biro, and 5,000 each to directors Brown, Mayer, Needham, Sitaraman
and Taussig at an exercise price of $3.06.
In addition, options to purchase 214,700 shares of the Company's common stock,
exercisable at $3.55 per share, were granted in connection with the 1994
acquisitions of Bioxytech and IBC. Mr. Rogers and Dr. Barker each received
20,000 of such stock options.
OPTION GRANTS IN LAST FISCAL YEAR
Options granted to executive officers of the Company who are included in the
Summary Compensation Table above for 1995 were as shown below:
<TABLE>
<CAPTION>
Individual Grants
- --------------------------------------------------------------------------------
Number of % of total
common shares options granted Exercise
underlying to employees price per Expiration
Name grant in 1995 share date
- ---- ------------- --------------- --------- --------------
<S> <C> <C> <C> <C>
Ray R. Rogers 45,000/1/ 16% $3.50 April 30, 2004
Anna D. Barker 25,000/1/ 9% $3.50 April 30, 2004
Jon S. Pitcher 35,000/2/ 13% $2.25 March 14, 2005
</TABLE>
- ------------------
/1/ The options granted to Mr. Rogers and Dr. Barker during 1995 became
exercisable during 1995.
/2/ The option granted to Mr. Pitcher during 1995 became exercisable as to
1/3 of the shares in 1995 and becomes exercisable as to an additional 1/3 of
the shares in each of 1996 and 1997.
11
<PAGE>
FISCAL YEAR END OPTION VALUES
During 1995, no options were exercised. All options issued to executive
officers who are included in the Summary Compensation Table above are shown
below.
<TABLE>
<CAPTION>
Number of
common shares Value of
underlying unexercised
unexercised in-the-money
options at options at
December 31, December 31,
Name 1995 1995
---- ---------------------------- ------------
Exercisable Unexercisable
------------- -------------
<S> <C> <C> <C>
Ray R. Rogers 65,000 $0
Anna D. Barker 60,000 $0
Jon S. Pitcher 23,334 12,459 $0
</TABLE>
PROPOSAL NO. 2 -- AMENDMENT TO THE COMPANY'S RESTATED CERTIFICATE OF
INCORPORATION (Item 2 on Proxy Card)
Increase in Number of Authorized Common Shares
The Board of Directors of OXIS has adopted a resolution to amend the first
paragraph of Article FOURTH of the Restated Certificate of Incorporation of OXIS
to read in its entirety as follows:
FOURTH: The Company is authorized to issue a total of forty million
(40,000,000) shares of Common Stock, each of which shares of Common
Stock has a par value of Fifty Cents ($.50). Dividends may be paid on
the Common Stock as and when declared by the Board of Directors, out
of any funds of the Company legally available for the payment of such
dividends, and each share of Common Stock will be entitled to one vote
on all matters on which such stock is entitled to vote. All duly
authorized One Dollar ($1.00) par value shares outstanding shall be
deemed shares having a par value of Fifty Cents ($.50).
The purpose of such amendment is to increase the number of authorized shares of
OXIS common stock from 25,000,000 to 40,000,000 shares. As of March 31, 1996,
OXIS had outstanding 12,124,423 shares of common stock and 11,387,644 shares of
common stock reserved for issuance as follows:
12
<PAGE>
<TABLE>
<CAPTION>
Common
shares
----------
<S> <C>
Common shares outstanding 12,124,423
Common shares reserved:
For conversion of
convertible securities:
Series B Preferred Stock 642,583
Series C Preferred Stock - maximum number of common
shares into which 4,000,000 Series C Preferred shares could
be converted 5,777,776
8% Convertible Subordinated Debentures - maximum
number of common shares into which outstanding debentures
could be converted 1,930,769
Outstanding warrants 1,621,817
Shares reserved for issuance under 1994 Stock
Incentive Plan 1,200,000/1/
Options outside the 1994 Stock Incentive Plan 214,699
----------
Total common shares outstanding or reserved 23,512,067
==========
</TABLE>
- -----------------
/1/ Proposal No. 3, if approved, will increase the number of shares
reserved for issuance under the 1994 Stock Incentive Plan to 2,200,000.
The OXIS Board believes that it is desirable for OXIS to have additional
authorized but unissued shares of OXIS common stock to provide flexibility to
act promptly with respect to acquisitions, public and private financing, stock
dividends and for other appropriate purposes. Approval of the increase now will
eliminate delays and the expense which otherwise would be incurred if
stockholder approval were required to increase the authorized number of shares
of OXIS common stock for possible future transactions involving the issuance of
additional shares. However, the rules of the NASD governing corporations with
securities listed on the NNM would still require stockholder approval by a
majority of the total votes cast in person or by proxy prior to the issuance of
designated securities (i) where the issuance would result in a change of control
of the Company, (ii) in connection with the acquisition of the stock or assets
of another company if an affiliate of the Company has certain interlocking
interests with the company to be acquired or where the Company issues more than
twenty percent (20%) of its currently outstanding shares or (iii) in connection
with a transaction other than a public offering involving the sale or issuance
of more than twenty percent (20%) of the common stock or voting power
outstanding before the issuance, subject to certain exceptions or application to
the NASD.
The additional shares of OXIS common stock may be issued, subject to certain
exceptions, by the Company's Board of Directors at such times, in such amounts
and upon such terms as the OXIS Board may determine without further approval of
the stockholders. Any such issuance could reduce the current stockholders'
13
<PAGE>
proportionate interests in OXIS or dilute the stock ownership of persons seeking
to obtain control of OXIS, depending on the number of shares issued and the
purpose, terms and conditions of the issuance. Stockholders have no preemptive
rights to subscribe to additional shares when issued.
Increase in Number of Authorized Preferred Shares
The second paragraph of Article FOURTH of the Restated Certificate of
Incorporation of OXIS is proposed to be amended to read in its entirety as
follows:
The Company is authorized to issue a total of Fifteen Million
(15,000,000) shares of Preferred Stock ($.01 par value), each of which
shares of Preferred Stock may be issued in one or more series of stock
within the class of Preferred Stock. Each series may have such voting
powers, full or limited, or no voting powers, and such designations,
preferences and relative, participating, optional or other special
rights, and qualifications, limitations or restrictions thereof, as
shall be stated and expressed in the resolution or resolutions
providing for the issue of such stock adopted by the Board of
Directors pursuant to authority hereby expressly vested in it by the
provisions of this Certificate of Incorporation.
The purpose of such amendment is to increase the number of shares of OXIS
preferred stock from 5,000,000 to 15,000,000. As of March 31, 1996, no shares
of Series A Preferred Stock, 642,583 shares of OXIS' Series B Preferred Stock
and 663,976 shares of OXIS' Series C Preferred Stock were outstanding.
The second paragraph of Article FOURTH empowers the Board of Directors, without
the necessity of further action or authorization by the stockholders (unless
required in a specific case by applicable laws, regulations or stock exchange
rules), to cause OXIS to issue preferred stock from time to time in one or more
series, and to fix by resolution the relative rights and preferences of each
series. The Series B and Series C Preferred Stock rank equal or senior to OXIS'
common stock with respect to dividends and liquidation rights. Each future
series of preferred stock will most probably also rank equal or senior to OXIS'
common stock with respect to dividends and liquidation rights.
The Restated Certificate of Incorporation authorizes the Board of Directors to
determine, among other things, with respect to each series of preferred stock
which may be issued: (i) the distinctive designation of such series of
preferred stock and the number of shares of preferred stock constituting such
series, (ii) the rate and preference of dividends payable on such preferred
stock, if any, the time of payment of dividends, provisions, if any, for the
accumulation of such dividends, and the date from which any dividend shall
accrue, (iii) the provisions of redemption of such preferred stock, if any, and,
if redeemable, the redemption price and the terms and conditions of redemption,
(iv) the amount payable to holders of such preferred stock upon voluntary or
involuntary liquidation, dissolution or winding up of OXIS, (v) purchase,
retirement, or sinking fund or other provisions, if any, for the purchase,
retirement or redemption of such preferred stock; (vi) the terms, rates of
conversion or exchange and conditions on which such preferred stock may be
converted or exchanged, if any, (vii) provisions, if any, as to voting rights
and the extent of such voting rights of such preferred stock, and (viii) any
other relative rights and preferences of such preferred stock, including,
without limitation, any restrictions on an increase in the number of capital
shares theretofore authorized and any limitation or restriction of rights or
powers to which preferred stock of any future series shall be subject. Holders
of common stock have no preemptive right to purchase or otherwise acquire any
preferred stock that may be issued in the future. The proposed amendment will
not change the number of shares of common stock currently authorized or
outstanding or the number of shares of preferred stock outstanding.
14
<PAGE>
This amendment will, in the opinion of the Board of Directors, increase OXIS'
financial flexibility. The Board believes that the complexity of business
financing and acquisition transactions require greater flexibility in OXIS'
capital structure than now exists. Preferred stock will be available in an
increased amount for issuance from time to time as determined by the Board for
any proper corporate purpose. Such purposes could include, without limitation,
issuance in public or private sales for cash as a means of obtaining capital for
use in OXIS' business and operations, issuance as part or all of the
consideration required to be paid by OXIS for acquisitions of other businesses
or properties, and issuance under employee benefit plans.
It is not possible to state the actual effect of the authorization of additional
preferred stock upon rights of holders of common stock until the Board
determines the respective rights of the holders of one or more future series of
preferred stock. The effects of such issuance could include, however: (i)
reduction of the amount otherwise available for payment of dividends on common
stock if dividends are payable on preferred stock, (ii) restrictions on
dividends on common stock if dividends on preferred stock are in arrears, (iii)
dilution of voting power of common stock if the preferred stock have voting
rights, and (iv) restriction of the rights of holders of common stock to share
in OXIS' assets upon liquidation preference granted to holders of preferred
stock.
The authorization of additional preferred stock improves the ability for the
Board of Directors to move promptly if appropriate opportunities or
contingencies should arise. If the proposed amendment is approved, the
consummation of any future plans to issue preferred stock may be facilitated
because the delay and expense of calling a special shareholders' meeting to
increase the number of authorized shares of preferred stock would be avoided
since the issuance of authorized preferred stock could be approved by the Board
of Directors without any further stockholder approval.
Voting or convertible preferred stock could be issued by private placement or
public offering, or rights to purchase such preferred stock could be issued, to
create voting impediments to or to frustrate persons seeking to effect a
takeover or otherwise to gain control of OXIS. The Delaware Corporations Code
permits the issuance of classes of shares with voting rights under which a
majority vote of the holders of each class, voting separately, is required to
approve a merger. Preferred stock could be issued with such rights to make
approval of a merger more difficult. The issuance of preferred stock could also
increase the absolute cost of a merger or other takeover transaction if the
price to be paid in such a transaction for such additional shares pursuant to
their terms or otherwise exceeds consideration received by OXIS upon issuance of
such shares.
This amendment could discourage an attempt by a person to acquire control of
OXIS by a tender offer or other means. It could therefore deprive stockholders
of benefits that could result from such an attempt, such as realization of a
premium over the market price of their shares in a tender offer or the temporary
increase in market price that such an attempt could cause. Moreover, the
issuance of voting preferred stock to persons friendly to the Board of Directors
could make it more difficult to remove incumbent management and directors from
office even if such change would be favorable to the stockholders generally.
The Board of Directors believes that the financial flexibility offered by the
amendment increasing the number of shares of authorized preferred stock far
outweighs any of its potential disadvantages. To the extent that it may have
anti-takeover effects, the amendment may encourage persons seeking to acquire
OXIS to negotiate directly with the Board, enabling the Board to consider the
proposed transaction in a nondisruptive atmosphere and to discharge effectively
its obligation to act on the proposed transaction in a manner that best serves
the stockholders' interest.
Vote Required
The approval of the amendment of OXIS' Restated Certificate of Incorporation
requires the affirmative vote of the holders of a majority of the outstanding
shares of OXIS common and preferred stock entitled to vote. Consequently,
abstentions will have the effect of a vote against the proposed amendment.
15
<PAGE>
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" APPROVAL OF THE AMENDMENT TO
OXIS' RESTATED CERTIFICATE OF INCORPORATION.
PROPOSAL NO. 3 -- APPROVAL OF AMENDMENT TO 1994 STOCK INCENTIVE PLAN
(Item 3 on Proxy Card)
The Company's Board of Directors and stockholders have previously approved the
adoption of the Company's 1994 Stock Incentive Plan (the "Plan") and the
reservation of 1,200,000 shares of the Company's common stock for issuance
thereunder. In April 1996, the Board of Directors authorized an amendment to
the Plan, subject to stockholder approval, to increase the shares reserved for
issuance thereunder by 1,000,000 shares, bringing the total number of shares
issuable under the Plan to 2,200,000. At the Annual Meeting, the stockholders
are requested to consider and approve the proposed amendment to the Plan to
increase the number of shares issuable under the Plan to 2,200,000. The OXIS
Board believes that adoption of the amendment to the Plan will ensure OXIS'
ability to attract and retain the best available individuals to serve as
employees, officers, directors, consultants, independent contractors and
advisors of OXIS.
Summary of the Plan
The Plan permits granting stock options to acquire shares of OXIS' common stock
("Options"), awarding stock bonuses of OXIS' common stock, selling shares of
OXIS' common stock and granting stock appreciation rights ("SARs")
(collectively, the "Awards"). Both incentive stock options ("ISOs") within the
meaning of section 422 of the Internal Revenue Code of 1986, as amended (the
"Code"), and nonqualified stock options ("NQSOs") may be granted under the Plan.
Awards under the Plan to other than directors of OXIS who are not employees of
either OXIS or a subsidiary of OXIS (the "Non-employee Directors") are not
determinable because such awards are made in the discretion of the OXIS Board or
its designated committee. See "Administration" below.
Purpose
The purposes of the Plan are to attract, retain and provide equity incentive to
selected persons to promote the financial success of OXIS. The OXIS Board of
Directors believes that it is essential to the future of OXIS that OXIS be in a
position to grant Awards under a stock incentive plan to selected employees,
officers, directors, consultants, independent contractors and advisors in order
for OXIS to remain competitive in attracting and retaining such individuals.
Administration
The Plan is administered by a committee of the Board of Directors of OXIS (the
"Plan Committee") comprised of at least two "disinterested persons" within the
meaning of Rule 16b-3(c)(2) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), although the plan could be administered by the OXIS Board
if it were comprised solely of "disinterested persons". The interpretation and
construction of any provision of the plan or any related agreement by the Plan
Committee is final and binding. With the exception discussed below in "Options
- - Non-Employee Director Formula Option Grants", the Plan Committee selects the
persons to whom Awards will be granted, determines the type of Award, the number
of shares to be covered by any Options or SARs awarded, the exercise price of
any such Options, the period during which any such Options may be exercised and
all other terms and conditions of Awards.
Eligibility
With the exception discussed below in "Options - Non-Employee Director Formula
Option Grants", the Plan provides that awards may be granted to employees,
officers, directors, consultants, independent contractors and advisors of OXIS
or any parent, subsidiary or affiliate of OXIS. ISOs may be granted only to
employees
16
<PAGE>
(including officers and directors who are also employees) of OXIS or any parent,
subsidiary or affiliate of OXIS. See "Certain United States Federal Income Tax
Information" below for information concerning the tax treatment of ISOs and
NQSOs.
As of March 31, 1996, there are eight directors of OXIS (six of whom are Non-
Employee Directors) and two OXIS officers (who are not directors) eligible to
participate in the Plan. There are approximately 59 employees of OXIS and its
subsidiaries who are not serving as officers who are also eligible to
participate. It is not possible to estimate the number of consultants,
independent contractors and advisors who are or may become eligible to
participate in the Plan.
Options
Grant of Options
- ----------------
The date of grant of an Option is the date on which the Plan Committee makes the
determination to grant the Option unless otherwise specified by the Plan
Committee. Option grants are evidenced by a written stock option grant and, if
for any reason a written stock option grant is not executed within sixty (60)
days of the date of grant, such Option grant shall be null and void. No
consideration shall be received by OXIS for the granting of Options. Subject to
the express provisions of the Plan, the exercise of an Option shall be subject
to such terms, conditions and restrictions as the Plan Committee may impose in
its sole discretion, including restrictions concerning transferability,
repurchase and forfeiture.
Options shall be exercisable on the terms set forth in the stock option grant;
provided that no Option shall be exercisable after the expiration of ten years
from the Option grant date. The Plan Committee may accelerate the earliest
exercise date of any Option.
The Plan states that there is a $100,000 limit to the aggregate fair market
value (calculated as set forth in "Option Price" below) of stock with respect to
which ISOs, whether granted under the Plan or any other ISO plan of OXIS or its
parent or subsidiary, are exercisable for the first time by an optionee during
any calendar year. The above limitations are driven by provisions of the Code
and are subject to change in the event that the relevant sections of the Code or
regulations promulgated thereunder are amended.
Option Price
- ------------
The exercise price of a NQSO shall be not less than eighty-five percent (85%) of
the fair market value of the shares underlying the Option on the date the Option
is granted. The exercise price of an ISO shall be no less than one hundred
percent (100%) of the fair market value of the shares on the date the Option is
granted, unless the person to whom the Option is granted is a ten percent (10%)
shareholder of OXIS in which case the exercise price shall be not less than one
hundred ten percent (110%) of the fair market value of the shares on the date
the Option is granted. The Plan Committee shall have the power, within certain
limitations, to reduce the exercise price of outstanding Options.
For purposes of the Plan, the fair market value of a share of OXIS' Common Stock
on a given date shall be the closing price on the NASDAQ National Market System
on the last trading day prior to the date of determination. The closing price
per share of OXIS' Common Stock on April 2, 1995, on the NASDAQ National Market
System was $1-7/8.
The method of payment for shares issued upon exercise of Options granted under
the Plan shall be determined by the Plan Committee and may consist of cash,
cancellation of indebtedness, other shares of common stock and certain other
methods permitted by law.
17
<PAGE>
Non-Employee Director Formula Option Grants
- -------------------------------------------
No ISOs, SARs or stock bonuses shall be awarded or shares sold to Non-Employee
Directors under the Plan. All grants of Options to Non-Employee Directors are
automatic and nondiscretionary. Accordingly, no person shall have any
discretion to select which such Non-Employee Directors shall be granted Options,
to determine when such Options may be granted or to determine the number of
shares of OXIS' Common stock to be covered by Options granted to such Non-
Employee Directors. All grants of Options to such Non-Employee Directors shall
be made in strict accordance with the following provisions:
(i) On the first business day following OXIS Board approval of the Plan, each
Non-Employee Director received a NQSO covering 15,000 shares. The OXIS Board
approved the Plan on June 15, 1994 and the closing price per share of OXIS'
Common Stock was $3.50. Non-Employee Directors appointed by the OXIS Board or
elected by the OXIS stockholders after such date shall receive a NQSO covering
15,000 shares on the first business day following such appointment or initial
election. Thereafter, annually on the first business day following the 1995
annual meeting of OXIS' stockholders and the first business day following each
annual meeting thereafter, each Non-Employee Director (other than one taking
office for the first time as a result of his or her election at such meeting and
therefore receiving a NQSO covering 15,000 shares) shall receive a NQSO covering
5,000 shares.
(ii) The exercise price of such options shall be equal to one hundred percent
(100%) of the fair market value of the shares on the date of grant determined as
set forth under "Option Price" above.
(iii) Such options shall be exercisable beginning six months after the date of
the grant and their term shall be ten years.
Stock Bonuses
The Plan Committee may award shares under the Plan as stock bonuses for no
consideration or for such minimum consideration as may be required by applicable
law in an amount and form as determined by the Plan Committee. An award of a
stock bonus shall be subject to such terms, conditions and restrictions as the
Plan Committee may impose in its sole discretion, including restrictions
concerning transferability, repurchase and forfeiture. The recipient of a stock
bonus must also satisfy any applicable federal, state or local tax withholding
requirements.
Stock Sales
The Plan Committee may issue shares of OXIS Common Stock under the Plan for such
amount (no less than par value) and form of consideration as determined by the
Plan Committee. A stock sale under the Plan shall be subject to such terms,
conditions and restrictions as the Plan Committee may impose in its sole
discretion, including restrictions concerning transferability, repurchase or
forfeiture. The purchaser must also satisfy any applicable federal, state or
local tax withholding requirements.
Stock Appreciation Rights
A SAR may be granted by the Plan Committee in tandem with an Option or as a
freestanding SAR. No consideration shall be received by OXIS for the granting
of SARs. Subject to the express provisions of the Plan, the exercise of a SAR
shall be subject to such terms, conditions and restrictions as the Plan
Committee may impose at its sole discretion, including restrictions concerning
transferability, repurchase and forfeiture. The recipient of a SAR must also
satisfy any applicable federal, state or local tax withholding requirements.
A SAR shall be exercisable only at the time or times established by the Plan
Committee; provided that no SAR shall be exercisable after the expiration of ten
years from the date the SAR was granted. If a SAR is granted in connection with
an Option, the SAR shall be exercisable only to the extent and on the same
conditions that the
18
<PAGE>
related Option could be exercised and, upon exercise of such a SAR, any Option
or any portion of such Option to which the SAR relates shall terminate.
Similarly, upon the exercise of an Option to which a SAR relates, the SAR or
portion thereof to which the Option relates shall terminate.
The Plan Committee may accelerate the earliest exercise date of any SAR.
Nonassignability of Options and SARs
Options and SARs granted pursuant to the Plan are nonassignable and
nontransferable by the optionee or recipient, other than by will or by the laws
of descent and distribution and may be exercised, during the lifetime of the
optionee or recipient, only by the optionee or recipient or any permitted
transferee.
Adjustment Upon Changes in Capitalization and Corporate Transactions
In the event that the number of outstanding shares of Common Stock of OXIS is
increased or decreased by a change in the capital structure of OXIS without
consideration, such as stock splits or dividends, or, if a substantial portion
of the assets of OXIS are distributed without consideration to the stockholders
of OXIS in a spin-off or similar transaction, appropriate adjustments shall be
made in the number or kind of shares available for Awards under the Plan, the
number or kind of shares subject to outstanding Options or SARs and the exercise
price per share of such Options.
In the event of a merger, consolidation, or similar occurrence where OXIS is not
the surviving corporation, or the sale of all or substantially all of the assets
of OXIS, each outstanding Award shall be assumed or substituted by such
successor corporation. In the event such successor corporation does not agree
to assume or substitute such Awards or to provide substantially similar
consideration to optionees or other recipients of Awards as was provided to
stockholders, or in the event of a dissolution or liquidation of OXIS, OXIS
shall notify each optionee or other recipient that the Awards shall expire on a
date at least twenty (20) days after OXIS gives such written notice.
Termination of Employment or Service Through Death, Disability or Otherwise
Under the Plan, in the event an optionee ceases to be employed by or to provide
services to OXIS or any parent or subsidiary of OXIS (and, in the case of a
NQSO, by or to any affiliate of OXIS) for any reason other than death or
permanent and total disability, any Option which was exercisable at the date of
termination may thereafter be exercised for a period of thirty (30) days. If
termination results from death or permanent and total disability, any Option
which was exercisable at the date of termination may thereafter by exercised for
a period of twelve (12) months. However, in no event may any Option be
exercised once its term has expired.
Plan Amendment and Termination
Except as described below, the Plan Committee may amend the Plan at any time or
may terminate the Plan without stockholder approval. However, except with
respect to SARs which may be withdrawn or amended at any time or may become
subject to retroactive rules and regulations, no action may be taken which would
impair the rights of any recipient of an Award without the consent of such
recipient, and the terms and conditions of formula grants to Non-Employee
Directors shall not be amended more frequently than permitted for formula plans
meeting the conditions of Rule 16b-3 promulgated by the SEC. In any event, the
Plan will terminate on April 30, 2004.
19
<PAGE>
Stockholder approval is required for certain specified amendments to the Plan,
including any amendment that increases the total number of shares for which
Awards may be granted, extends the duration of the Plan, extends the period
during and over which Options or SARs may be exercised under the Plan, or
changes the class of persons eligible to receive awards granted under the Plan
(except as may be required to comport with changes in the Code, ERISA or
regulations promulgated thereunder).
Certain United States Federal Income Tax Information Regarding Options
Options granted under the Plan may be either ISOs, as defined in Section 422 of
the Code, or NQSOs.
Incentive Stock Options
- -----------------------
If an option granted under the Plan is an incentive stock option, the optionee
will recognize no income under the grant of the incentive stock option and incur
no tax liability at the time of exercise unless the optionee is subject to the
alternative minimum tax. OXIS will not be allowed a deduction for federal
income tax purposes as a result of the exercise of the incentive stock option
regardless of the applicability of the alternative minimum tax. Upon the sale
or exchange of the shares at least two years after the grant of the option and
one year after receipt of the shares by the optionee, any gain will be treated
as long-term capital gain. If these holding periods are not satisfied, the
optionee will recognize ordinary income equal to the difference between the
exercise price and the lower of the fair market value of the stock at the date
of option exercise or the sale price of the stock. OXIS will be entitled to a
deduction in the same amount as the ordinary income recognized by the optionee.
Nonqualified Stock Options
- --------------------------
All options which do not quality as incentive stock options under the Code are
referred to as nonqualifed stock options. Generally, an optionee will not
recognize any taxable income at the time the optionee is granted a nonqualified
stock option. However, upon exercise of the option, the optionee will recognize
ordinary income for income tax purposes equal to the excess of the then fair
market value of the shares over the option price. The income recognized by an
optionee who is also an employee of OXIS will be subject to tax withholdings by
OXIS by payment in cash or out of the current earnings paid to the optionee.
OXIS will be allowed a deduction for federal tax purposes in an amount equal to
the income recognized by the optionee so long as OXIS has met all applicable
withholding requirements and so long as the exercise of the option by optionee
does not cause OXIS to violate the limits on executive compensation set forth in
Section 162(m) of the Code. If the optionee holds such shares for more than one
year following exercise of the option, any gain realized upon disposition will
be treated as long-term capital gain. If the shares are sold within one year
after the exercise date, any gain realized upon disposition will be treated as
short-term capital gain. The gain realized upon disposition will be the excess,
if any, of the sales price over the tax basis of the shares.
Tax Summary Only
- ----------------
The foregoing summary of the effect of federal income taxation upon the optionee
and OXIS with respect to the purchase of OXIS' shares under the Plan does not
purport to be complete, and reference should be made to the applicable
provisions of the Code. In addition, the summary does not discuss the
provisions of the income tax laws of any municipality, state, or foreign
country.
Options Received by Certain Persons
Options granted under the 1994 Stock Incentive Plan to certain individuals and
groups of individuals since the inception of the Plan are set forth below:
20
<PAGE>
<TABLE>
<CAPTION>
Number of
Common Shares
Underlying Grant
----------------
<S> <C>
Executive officers included in Summary Compensation Table:
Ray R. Rogers, Chairman 85,000
Anna D. Barker, President and Chief Executive Officer 80,000
Jon S. Pitcher, Vice President, Chief Financial Officer
and Secretary 60,000
Nominees for election as directors, other than Rogers and Barker, above:
Timothy G. Biro 20,000
Stuart S. Lang 15,000
James D. McCamant 15,000
Gerald D. Mayer, Ph.D. 20,000
David A. Needham, Ph.D. 20,000
A.R. Sitaraman 20,000
Other recipients of at least 5% of options available:
Timothy C. Rodell 300,000
Lynda M. Taylor 60,000
Peter E. Taussig 55,000
All current executive officers, as a group 525,000
All current directors who are not executive officers,
as a group 110,000
All employees, excluding executive officers, as a group 210,500
</TABLE>
Stockholder Rights
The recipient of an Award shall have no rights as a stockholder of OXIS with
respect to any shares until the date such recipient is issued a stock
certificate for such shares of OXIS.
Vote Required
The approval of the amendment of OXIS' 1994 Stock Incentive Plan requires the
affirmative vote of the holders of a majority of the outstanding shares of OXIS
common and preferred stock entitled to vote. Consequently, abstentions will
have the effect of a vote against the proposed amendment.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" APPROVAL OF THE
AMENDMENT TO OXIS' 1994 STOCK INCENTIVE PLAN AND THE RESERVATION OF AN
ADDITIONAL 1,000,000 SHARES FOR ISSUANCE THEREUNDER. UNLESS OTHERWISE DIRECTED
BY A STOCKHOLDER, PROXIES WILL BE VOTED "FOR" ADOPTION OF THIS AMENDMENT OF THE
1994 STOCK INCENTIVE PLAN AND RESERVATION OF AN ADDITIONAL 1,000,000 SHARES FOR
ISSUANCE THEREUNDER.
21
<PAGE>
SELECTION OF INDEPENDENT AUDITORS
Deloitte & Touche LLP has been selected to act as the Company's principal
accountant for the fiscal year ending December 31, 1996. Representatives of
Deloitte & Touche are expected to be present at the Annual Meeting with the
opportunity to make a statement if they desire to do so and to respond to
questions of stockholders.
INFORMATION INCORPORATED BY REFERENCE
Certain information required to be disclosed in connection with Proposal No. 2
is incorporated herein by reference from the material contained on pages 7
through 26 of the Company's 1995 Annual Report to Shareholders.
OTHER MATTERS
The Board of Directors of the Company knows of no other matters which are to be
brought before the meeting. If any other matters should be presented for proper
action, it is the intention of the persons named in the Proxy to vote in
accordance with their discretion pursuant to the terms of the Proxy.
It is important the Proxies be returned promptly. Therefore, stockholders who
do not expect to attend the meeting in person are urged to fill in, sign, date
and return the enclosed Proxy.
A copy of the Company's Annual Report for the fiscal year ended December 31,
1995, filed with the Securities and Exchange Commission, is being delivered
simultaneously herewith to each stockholder of the Company of record as of April
19, 1996.
The Company's stock transfer agent and registrar is Boston EquiServe, P.O. Box
644, Boston, MA 02102. Telephone: (800) 442-2001.
OXIS INTERNATIONAL, INC.
By Anna D. Barker, Ph.D.
President and Chief Executive Officer
22
<PAGE>
OXIS International Inc. develops,
manufactures and markets a series of
therapeutic and diagnostic products. Our
research and development efforts are
concentrated primarily on the development of
products to diagnose, treat and prevent
diseases associated with free radicals and
reactive oxygen species. We are pursuing drug
discovery with a method of operation that
represents a different model for biomedical
companies.
Our model is to fund our research and
development through alliances with
pharmaceutical companies and with revenues
from generic diagnostic assays and our
growing presence in the area of diagnostic
assays for markers of oxidative stress. Over
the next two years we expect to establish the
relevance of these assays in the clinical arena,
where oxidative stress profiles could become
an important part of the booming "Wellness"
market.
Longer term, we see the potential for our
growth in the development of therapeutics for
diseases not now adequately addressed by
available medications. Oxidative stress has
been recognized as a basic mechanism of
disease and our therapeutic programs target
high-value markets. These include
cardiovascular disease and a number of
inflammatory diseases -- inflammatory bowel
disease, cataracts and arthritis. Our two most
advanced programs are moving ahead
aggressively, and we hope to achieve the
milestone of initial human clinical trials for
one or more compounds over the next 18
months.
<TABLE>
<CAPTION>
Table of Contents
<S> <C>
Letter to Shareholders 2
Management's Discussion and
Analysis 7
Selected Financial Data 10
Consolidated Financial Statements 11
Notes to Consolidated Financial
Statements 15
Independent Auditors' Report 26
Officers and Directors 27
Corporate Information 28
</TABLE>
[LOGO OF OXIS INTERNATIONAL, INC.]
1
<PAGE>
L E T T E R T O S H A R E H O L D E R S
[LOGO OF OXIS International, Inc.]
April 30, 1996
Dear Fellow Shareholders;
OXIS International, Inc. (OXIS) undertook several key initiatives in
1995 to position the Company for a successful future. As a result, we
enter 1996 with a clear focus and the organizational capabilities to
meet our scientific and business challenges and achieve our mission.
During 1995, we made substantial progress in increasing the value of our
diagnostics and therapeutics technology portfolio; at the same time, our
business and technology focus is now more synergistic due to the
downsizing and integration of our operations. Further, the addition of
new products and key distributors for our diagnostics led to improved
current revenues for selected products and enhanced the potential for
future gains in revenues. We also successfully completed the acquisition
of Therox Pharmaceuticals, Inc. (Therox) a private company with
excellent therapeutics technology that both complements and
strategically strengthens our current portfolio of novel anti-oxidant
molecules. Finally, we successfully raised approximately $6 million to
support our strategic plan for the Company.
Specific highlights of 1995 included:
OXIS enhanced the value of its technology portfolio and made significant
progress in the preclinical development of two key therapeutics programs.
Through the acquisition of Therox, we added several key antioxidant
technologies, including "platform" antioxidant compounds that can be
used to create bifunctional molecules. For example, we can add enzyme
inhibitors, or other functional groups, to these antioxidant molecules
in order to treat complex inflammatory diseases. This acquisition also
brought ten patents and several additional patent applications,
collaborative relationships with key university scientists and several
additional series of antioxidant molecules that could produce
significant revenue for the Company in the near term.
Perhaps of most importance, we successfully focused our efforts in the
discovery and development of novel antioxidant molecules and selected
two key programs to move forward as quickly as possible into initial
human clinical trials. These are the glutathione peroxidase mimics
program (GPx), developed in our French laboratories, and our membrane
active lipid soluble antioxidants (LSA), acquired through the Therox
transaction.
As a result of this strategic focus, our international project teams
have acquired exciting new data on both series of molecules that
suggests a revolutionary level of cellular protection. The lead GPx
molecule has shown activity in animal models,
2
<PAGE>
including models for inflammatory bowel disease and for acute hepatitis.
In preliminary experiments, both series of molecules have also shown the
ability to inhibit a factor called NFk-B, a genetic factor that we
believe plays a key role in the inflammatory process. These early
findings suggest that two of our lead LSA molecules may be active at
lower levels than previously reported for other active molecules. We are
currently repeating and extending these studies to further clarify the
role of our molecules ias potential NFk-B inhibitors. We are pleased to
report that we have also met all of our regulatory milestones to date for
the GPx mimics program, which should allow us to perform initial human
clinical trials this year. The LSA lead molecule will follow the GPx
program by several months.
We were successful in licensing a beta-lactamase diagnostic technology to
Becton-Dickinson for use in their product line. We also made progress in
the development of improved forms of two of our research assays that
should reach the market in 1996. These assays are discussed more fully
below.
The Company integrated and reorganized to improve the efficiency and
effectiveness of our operations.
During 1995, we successfully integrated support functions for our
domestic and Paris operations and initiated efforts to eliminate
redundant capabilities. As a result, we closed our facility in Mountain
View, California, and relocated the development programs to Portland. We
also selectively reduced staff across the Company and will add critical
key staff in 1996. For example, Dr. Tim Rodell has recently joined us as
our Chief Operating Officer. Dr. Rodell is a physician with extensive
experience in operations, clinical trials and drug development. During
his tenure at Cortech, Inc., he was responsible for preclinical
development of three drugs now in clinical trials and conducted
international Phase I and Phase II clinical trials. We will continue our
program to optimize the synergy of our operations and build our staff
through selective recruiting.
In 1995, OXIS improved revenues, added diagnostic products and acquired key
new distributors for our research and commercial assays.
We are pleased with the acceptance by the research community of our
assays to measure markers of oxidative stress. We increased our revenues
from these assays 25%. This was accomplished in part due to the
development of relationships with the key distributors of research
products, including Calbiochem, R&D Systems U.S., and Boheringer
Ingelheim. We enhanced our generic diagnostics business through the
addition of a line of drugs-of-abuse assays and an exclusive assay,
developed by OXIS, for the new anti-seizure drug, topiramate. We believe
these products have significant revenue potential. Our goals for 1996 and
beyond are to maximize revenues from our generic diagnostics, increase
sales of our research
3
<PAGE>
assays for markers of oxidative stress and utilize these research assays
to create an oxidative stress profile that can be sold to the "Wellness"
market.
It should be noted that OXIS' overall revenues were hurt when
Sanofi Winthrop's Phase III clinical trial for head trauma failed to
reach statistical significance. OXIS had previously supplied bovine
superoxide dismutase (SOD) to Sanofi Winthrop for this program.
Fortunately, the Company had developed an alternative business strategy
that integrated our synthetic pharmaceutical research and development
programs with our markers of oxidative stress, so the closure of this
market for bovine SOD did not significantly impact our plans for the
future.
OXIS raised significant funds to finance is research and development programs
and successfully completed a strategic acquisition in 1995.
Among the key challenges the Company faced in 1995 was the requirement to
raise funds to strategically accelerate the preclinical development of
its two lead therapeutics programs. The successful completion of initial
human clinical trials will be a major factor in attracting pharmaceutical
alliance partners for the clinical development of our therapeutic
molecules. The Company was successful in raising approximately $4.5
million from private sources and previous investors, and an additional
$1.5 million from S.R. One, Limited (venture investment arm of SmithKline
Beecham) and Brantley Venture Partners as part of the Therox acquisition.
The acquisition of Therox enhanced our strategic focus on the discovery
and development of novel synthetic antioxidant molecules by significantly
broadening our technology and patent portfolio. In fact, one of our two
focus pharmaceutical programs, the LSA series, came from the Therox
portfolio.
We believe that our success in meeting these and other challenges in 1995
has positioned the Company to achieve key milestones in 1996 and beyond.
FINANCIAL REVIEW
Total revenues for 1995 were $5,136,000. The Company's total sales for
1995 reflected both new initiatives to increase the sales of research and
generic diagnostic products, which resulted in sales of $2,240,000, and
an overall reduction in bulk bSOD sales to $1,817,000 due primarily to
reduced sales to Sanofi Winthrop. Sales of the Company's veterinary
product, Palosein, exceeded $500,000 for 1995.
Total expenses for 1995 totaled $13,899,000 and reflected investments in
R&D programs; expenses related to the Therox acquisition; costs
associated with integration and closure of the Mountain View facility;
expenses associated with raising capital; and sales and marketing costs.
Expenses also included a charge to
4
<PAGE>
operations of $3,329,000 in 1995 that reflects a write-off of the
in-process technology acquired as part of the Therox acquisitions. A
similar charge of $3,675,000 was recorded in 1994 in connection with
previous acquisitions.
OXIS enters 1996 with an ongoing requirement for funding from external
investors primarily to support our pharmaceutical R&D programs. The
Company has engaged an agent to raise up to $4,000,000 on a best efforts
basis through the sale of Series C preferred stock and plans to raise
additional funds later in 1996.
1996 AND BEYOND
OXIS' path to the future is based on a synergistic combination of
research and commercial diagnostic products and potential new
therapeutics in the rapidly developing field of oxidative stress.
Revenue generated through the sale of both our research and commercial
assays will partially support development costs for our new
therapeutics. In addition, we anticipate that our assays for markers of
oxidative stress will provide a powerful developmental synergy with our
therapeutic products in terms of future clinical monitoring.
The research markets for our assays to measure markers of oxidative
stress is growing rapidly. The increased use of these assays by basic
and clinical researchers will support the developing global
knowledge-base required to make therapeutic antioxidants clinically
effective. One of the cornerstones of our strategy is to remain the
leader in the development and sale of these research assays and to
expand their use into the emerging "Wellness" market. We plan to make
our assays available in combination(s) to perform "profiles" for this
market. OXIS can envision the eventual routine application of
antioxidant diagnostic assays for a large segment of the U.S. population
as environmental conditions and other factors affecting wellness are
linked to diseases of oxidative stress.
OXIS has the resources in place to manufacture and sell its current and
future lines of research and commercial diagnostics. The Company
expects revenue from sale of our assays and profiles to monitor
oxidative stress to be significant. Our plan is to retain manufacturing
and marketing rights to our oxidative stress assays to maximize both
their economic and scientific value to OXIS.
OXIS believes that its pipeline of new synthetic antioxidant
technologies is the strongest in the industry. We have focused our R&D
investments on two complimentary programs (GPx mimics and LSA programs)
to address key biochemical targets within the cell and at the cell
membrane level. Data from these two programs suggests that OXIS'
molecules are acting at a very important point in the inflammatory
process. We plan to achieve initial human clinical trials as soon as
possible, complete required regulatory filings and seek "preferred"
strategic alliance partners.
5
<PAGE>
OXIS' additional series of novel antioxidant molecules and other
therapeutic compounds represent a major source of intellectual property
for the Company in terms of seeking additional business partners. We
anticipate that certain of these technologies could produce significant
revenue from license and alliance arrangements.
OXIS is well positioned in an increasingly important area of scientific
discovery and product development -- diseases related to damage from
free radicals and reactive oxygen species. The Company's focus
therapeutic programs are "cutting-edge" in terms of current scientific
understanding of the inflammatory process. Our scientific and management
teams are well-trained and experienced in their respective scientific
disciplines and jobs. As in 1995, our requirement for outside investment
to fund our R&D programs will continue to be a major challenge; but as
we build the value of our technologies, we improve the position of the
Company for a future public offering.
In closing, we appreciate your past support and look forward with you to
enhanced shareholder value through the successful growth of OXIS.
Anna D. Barker, Ph.D. Ray R. Rogers
President and CEO Chairman of the Board
6
<PAGE>
Management's Discussion and Analysis of Financial Condition and
Results of Operations
ACQUISITIONS
In September 1994, the Company significantly increased its scientific and
technical staff, patent application portfolio, current product offerings,
research and development programs, research and manufacturing facilities and its
customer base by acquiring Bioxytech S.A. (now "OXIS S.A.") and International
BioClinical, Inc. (IBC) (together the "1994 acquired businesses"). Both
acquisitions were completed through the exchange of stock, and were accounted
for as purchases; accordingly, the acquired assets and liabilities were recorded
at their estimated fair values as of the date of acquisition. IBC was merged
into the Company. OXIS S.A. operates as a subsidiary of the Company.
In July 1995, in a transaction which was also accounted for as a purchase, the
Company acquired Therox Pharmaceuticals, Inc. (Therox) through an exchange of
stock. Therox was merged into a wholly-owned subsidiary of the Company. The
acquisition of Therox provided the Company with a technology portfolio
complementary to its novel therapeutics for treatment of free radical associated
diseases together with university partnerships and seven patents.
Because the acquisitions have been accounted for as purchases, the Company's
consolidated results of operations include the operating results of the acquired
businesses from the dates of acquisition only. Therefore, the results of
operations of the 1994 acquired businesses are included in the consolidated
statements of operations from September 7, 1994, and the results of Therox's
operations are included in the consolidated statements of operations from July
19, 1995.
Costs relating to the acquisitions and the Company's more complex corporate
structure and the increased research and development investments have placed
significant demand on the Company's limited financial resources. See "Financial
Condition, Liquidity and Capital Resources" below.
FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES
During 1995 the Company's working capital deficit increased from $1,046,000 at
December 31, 1994, to $1,469,000 at December 31, 1995. This increase in the
Company's working capital deficit resulted primarily from the effect of the net
loss for 1995 ($8,892,000 less non-cash charges of $4,698,000), offset by
proceeds from issuance of stock ($2,925,000) and long-term debt ($1,255,000).
Shareholders who hold $766,000 of notes that are included in current liabilities
at December 31, 1995 have commitments to invest an amount at least equal to the
note balances in equity securities of the Company. During March 1996 the
Company is negotiating with these shareholders terms for converting these notes
to stock of the Company. If all such notes are converted to Company stock, the
Company's working capital deficit will be reduced by $766,000.
Cash and certificates of deposit declined from $1,432,000 at December 31, 1994,
to $727,000 at December 31, 1995.
The Company expects to continue to report losses in the near term as the level
of expenses is expected to continue to exceed revenues. The Company must raise
additional capital during the first half of 1996. Failure to raise such
additional capital would cause the Company to severely curtail or cease
operations. For more information concerning the Company's ability to continue
as a going concern, see Note 1 to the consolidated financial statements.
While the Company believes that its new products and technologies show
considerable promise, its ability to realize significant revenues therefrom is
dependent upon the Company's success in developing business alliances with
biotechnology and/or pharmaceutical companies that have the required resources
to develop and market certain of these products. These is no assurance that the
Company's effort to develop such business alliances
7
<PAGE>
will be successful. Further, bovine superoxide dismutase sales of recent years
to Sanofi Winthrop Inc. (18% of 1995 revenues) are not expected to continue.
Sanofi Winthrop announced in October 1995 that a second Phase III trial on its
drug, DISMUTEC/TM/ (a coupled form of OXIS' bovine superoxide dismutase) to
treat head trauma failed to show statistically significant improvements between
the treatment and control groups. Although the Company is currently seeking
additional funds through a private placement (described below), it cannot
predict the source, terms, amount, form, and/or availability of additional
capital to fund its operations to the end of the current year.
The Company has engaged an agent to assist on a best-efforts basis to raise up
to $4,000,000 in the first quarter of 1996 through the sale of its Series C
Preferred Stock. On March 4, 1996, the Company announced the first closing of
the offering, with proceeds of $763,000 from the sale of Series C Preferred
Stock. Even if the Company is able to sell the entire $4,000,000 of Series C
Preferred Stock, it expects that additional capital will be required during 1996
to continue operating in accordance with its current plans. However, no
assurances can be given that the Company will successfully raise the needed
capital. If the Company is unable to raise additional capital during the
remainder of 1996, it would endeavor to extend its ability to continue in
business through the reduction of personnel and facility costs, by slowing its
research and development efforts, and by reducing other operating costs,
however, no assurances can be given that it will be able to do so.
------------------------------------------------------------
RESULTS OF OPERATIONS
Revenues
The Company's sales for the past three years consisted of the following:
<TABLE>
<CAPTION>
1995 1994 1993
---------- ---------- ----------
<S> <C> <C> <C>
Diagnostic and research assays $2,240,000 $ 645,000 $ --
Bovine superoxide dismutase (bSOD)
for research and human use 1,817,000 2,130,000 2,098,000
Palosein(R) (bSOD for veterinary use) 555,000 346,000 123,000
Other 370,000 204,000 94,000
---------- ---------- ----------
Total sales $4,982,000 $3,325,000 $2,315,000
========== ========== ==========
</TABLE>
------------------------------------------------------------
Diagnostic and research assays are products acquired with the acquisitions of
IBC and OXIS S.A. Sales of these products for 1994 represent sales from
September 8 through the end of the year. The entire year's sales of diagnostic
and research assays are included in the Company's sales for 1995.
Reductions of bulk bSOD sales to Sanofi Winthrop and to the Company's German
licensee in 1994 were offset by an increase in sales to the Company's Spanish
licensee, resulting in a slight increase in bulk bSOD sales in 1994.
In 1995 bulk bSOD sales to Sanofi Winthrop declined further, and there were no
sales to the Company's German licensee. These decreases were partially offset by
a further increase in sales to the Spanish licensee.
Since no further sales of bSOD to either Sanofi Winthrop or the Company's German
licensee are anticipated, future sales of bulk bSOD are largely dependent on the
needs of the Company's Spanish licensee. Although the Spanish licensee has
continued to purchase bSOD in the first quarter of 1996, the Company has
received no further firm
8
<PAGE>
orders for bSOD beyond what has been shipped in the first quarter of 1996.
Thus, the Company's sales of bulk bSOD for 1996 and beyond are uncertain and
difficult to predict and no assurances can be given with respect thereto.
Sales of Palosein(R), which was reintroduced to the U.S. market in 1993 and is
sold primarily to veterinary wholesalers in the United States, increased from
$123,000 in 1993 to $346,000 in 1994 and $555,000 in 1995 as a result of an
active direct mail marketing campaign, which the Company intends to continue.
Royalty income in 1994 declined to $145,000, from $729,000 in 1993. As
discussed in Note 12 to the consolidated financial statements, the Company
anticipates that royalties from licensees of its bSOD products will be minimal
in the future because of the recent regulatory developments in Europe. A
further decline in royalties in 1995 was offset by a fee generated from an
agreement to license rights to the Company's technology for the rapid detection
of antibiotic resistance.
Costs and Expenses
Cost of sales as a percent of product sales increased from 57% in 1993 to 62% in
1994. This increase in cost was partially due to the inclusion, in 1994, of
sales and cost of products of the businesses acquired in September 1994. The
cost of those products includes the amortization of acquired technology
($239,000 in 1994 and $727,000 in 1995). In addition, the cost of bulk bSOD
sales in 1994 was higher than usual due to a significant sale at less than the
Company's historic profit margin. Cost of sales as a percent of product sales
declined from 62% in 1994 to 59% in 1995. In 1995 the cost of the Company's
diagnostic and research assays declined slightly as a result of increased
volumes, and the cost of bulk bSOD sales also declined from the 1994 level.
Research and development costs increased from $813,000 in 1993 to $1,670,000 in
1994 and $4,299,000 in 1995. The increases were primarily due to the cost of
the research and development activities associated with pharmaceutical
technologies acquired in the September 1994 and July 1995 business acquisitions.
Sales, general and administrative expenses increased from $1,008,000 in 1993 to
$1,652,000 in 1994. This increase was due to the inclusion of general and
administrative costs of the acquired businesses after the September 1994
acquisitions, other current expenses relating to the acquisitions, increases in
insurance coverage, and increased marketing costs relating to Palosein(R) and
new products from the 1994 acquisitions.
Sales, general and administrative expenses increased further in 1995 to
$3,332,000. The increase in 1995 was due primarily to the inclusion for the
entire year of general and administrative costs of the businesses acquired in
1994, further increases in sales and marketing costs relating to Palosein(R) and
the new products from the 1994 acquisitions, and increased legal fees and other
expenses relating to the Company's ongoing need to raise capital and more
complex corporate structure.
Expenses included charges of $3,675,000 and $3,329,000 to operations for 1994
and 1995, respectively, reflecting the write-off of purchased in-process
technology, as described in Note 3 to the consolidated financial statements.
Interest Income and Expense
Interest income decreased and interest expense increased in both 1994 and 1995
as the Company liquidated certificates of deposit and borrowed funds pursuant to
short-term and long-term interest bearing obligations to finance increased
research and development efforts.
9
<PAGE>
Net Loss
The Company incurred net losses in 1993, 1994 and 1995. In 1993 the Company
recorded non-recurring costs and expenses of $1,531,000 ($.31 per share)
relating to a contest for control of the Company. The 1994 loss includes a
$3,675,000 ($.58 per share) charge to operations for the write-off of purchased
in-process technology related to the acquisitions of OXIS S.A. and IBC.
Similarly, the 1995 loss includes a $3,329,000 ($.31 per share) charge to
operations for the write-off of purchased in-process technology related to the
acquisition of Therox. Excluding these unusual charges, the Company would have
incurred a net income of $46,000, or $.01 per share for 1993; a net loss of
$1,892,000, or $.30 per share for 1994; and a net loss of $5,563,000, or $.51
per share for 1995.
Increased research and development expenditures and selling, general and
administrative expenses from the businesses acquired late in the third quarter
of 1994 and increased research and development expenditures relating to the
acquisition of Therox early in the third quarter of 1995 contributed to the
increased losses.
The Company expects to incur a substantial net loss for 1996. If additional
capital is raised through further sales of securities (See Financial Condition,
Liquidity and Capital Resources), the Company plans to continue to invest in
research and development activities and incur sales, general and administrative
expenses in amounts greater than its anticipated near-term product margins. If
the Company is unable to raise sufficient additional capital, it will have to
cease, or severely curtail, its operations. In this event, while expenses will
be reduced, expense levels, and the potential write down of various assets,
would still be in amounts greater than anticipated revenues.
------------------------------------------------------------
------------------------------------------------------------
Selected Financial Data
<TABLE>
<CAPTION>
For years ended
December 31: 1995 1994 1993 1992 1991
------------ --------------- --------------- ----------- -----------
<S> <C> <C> <C> <C> <C>
Total Revenues/1/ $ 5,136,000 $ 3,470,000 $ 3,044,000 $2,772,000 $2,650,000
Net loss $(8,892,000)/2/ $(5,567,000)/3/ $(1,485,000)/4/ $ (339,000) $ (193,000)
Net loss per share $ (.82)/2/ $ (.88)/3/ $ (.30)/4/ $ (.07) $ (.04)
As of December 31:
Total assets $ 9,870,000 $11,194,000 $ 3,124,000 $4,864,000 $4,770,000
Long-term
obligations $ 1,332,000 $ 376,000 -- -- --
Common shares
outstanding 12,124,423 9,322,762 4,982,670 4,982,670 4,982,670
</TABLE>
- --------------------
/1/ Earned interest not included in revenue.
/2/ Includes a charge of $3,329,000 ($.31 per share) for the write off of
certain technology of an acquired company.
/3/ Includes a charge of $3,675,000 ($.58 per share) for the write off of
certain technology of acquired companies.
/4/ Includes a charge of $1,531,000 ($.31 per share) for control contest
expense.
As explained under the caption "ACQUISITIONS" in Management's Discussion and
Analysis of Financial Condition and Results of Operations above, the Company
made significant acquisitions during 1994 and 1995 that affect the comparability
of the amounts reflected in the table above.
10
<PAGE>
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 1995 AND 1994
<TABLE>
<CAPTION>
1995 1994
------------- -------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 727,000 $ 936,000
Certificates of deposit -- 496,000
Accounts receivable 823,000 740,000
Inventories 953,000 673,000
Prepaid and other 262,000 228,000
------------ ------------
Total current assets 2,765,000 3,073,000
Property and equipment, net 1,092,000 1,298,000
Assets under capital leases, net 1,198,000 1,340,000
Technology for developed products and
custom assays, net 4,498,000 5,215,000
Other assets 317,000 268,000
------------ ------------
Total assets $ 9,870,000 $ 11,194,000
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Note payable to bank $ -- $ 340,000
Other notes payable 1,616,000 --
Accounts payable 1,182,000 1,562,000
Customer deposits 250,000 1,116,000
Accrued liabilities 903,000 628,000
Current portion of capital lease obligations 283,000 473,000
------------ ------------
Total current liabilities 4,234,000 4,119,000
Capital lease obligations 47,000 297,000
8% convertible subordinated debentures 1,255,000 --
Other liabilities 30,000 79,000
Commitments and contingencies (Notes 1, 3 and 11)
Shareholders' equity:
Preferred stock - $.01 par value; 5,000,000 shares
authorized; 642,583 issued and outstanding
(liquidation preference of $1,500,000) 6,000 --
Common stock - $.50 par value; 25,000,000 shares
authorized; 12,124,423 shares issued and outstanding 6,062,000 4,661,000
Additional paid in capital 25,210,000 20,230,000
Accumulated deficit (27,031,000) (18,139,000)
Accumulated translation adjustments 57,000 (53,000)
------------ ------------
Total shareholders' equity 4,304,000 6,699,000
------------ ------------
Total liabilities and shareholders' equity $ 9,870,000 $ 11,194,000
============ ============
</TABLE>
See accompanying notes.
11
<PAGE>
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993
------------- ------------ ------------
<S> <C> <C> <C>
Revenues:
Sales $ 4,982,000 $ 3,325,000 $ 2,315,000
Royalties and license fees 154,000 145,000 729,000
----------- ----------- -----------
Total revenues 5,136,000 3,470,000 3,044,000
Costs and expenses:
Cost of sales 2,939,000 2,074,000 1,330,000
Research and development 4,299,000 1,670,000 813,000
Sales, general and administrative 3,332,000 1,652,000 1,008,000
Purchased in-process technology (Note 3) 3,329,000 3,675,000 --
Control contest -- -- 1,531,000
----------- ----------- -----------
Total costs and expenses 13,899,000 9,071,000 4,682,000
----------- ----------- -----------
Operating loss (8,763,000) (5,601,000) (1,638,000)
Interest income 42,000 82,000 153,000
Interest expense (171,000) (48,000) --
----------- ----------- -----------
Net loss $(8,892,000) $(5,567,000) $(1,485,000)
=========== =========== ===========
Net loss per share $(0.82) $(0.88) $(0.30)
=========== =========== ===========
Weighted average number of shares
used in computation 10,854,149 6,350,097 4,982,670
=========== =========== ===========
</TABLE>
See accompanying notes.
12
<PAGE>
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993
------------ ------------ ------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss $(8,892,000) $(5,567,000) $(1,485,000)
Adjustments to reconcile net loss to cash provided
by (used for) operating activities:
Depreciation and amortization 1,369,000 551,000 53,000
Purchased in-process technology 3,329,000 3,675,000 --
Changes in assets and liabilities:
Accounts receivable (70,000) 258,000 201,000
Inventories (17,000) (186,000) (105,000)
Other current assets 209,000 (19,000) 12,000
Accounts payable (565,000) 562,000 (248,000)
Customer deposits (866,000) 1,116,000 --
Accrued liabilities 251,000 (8,000) (7,000)
----------- ----------- -----------
Net cash provided by (used for)
operating activities (5,252,000) 382,000 (1,579,000)
Cash flows from investing activities:
Redemption of certificates of deposit 496,000 884,000 2,098,000
Purchase of equipment (99,000) (40,000) (69,000)
Acquisition and stock issuance costs (Note 3) -- (1,361,000) --
Cash of businesses acquired (Note 3) 143,000 273,000 --
Other (136,000) 19,000 --
----------- ----------- -----------
Net cash provided by (used for)
investing activities 404,000 (225,000) 2,029,000
Cash flows from financing activities:
Short-term borrowing 1,366,000 296,000 --
Proceeds from issuance of long-term debt 1,255,000 -- --
Costs in connection with issuance of long-term debt (152,000) -- --
Proceeds from issuance of stock, net of related cost 3,077,000 -- --
Repayment of short-term notes (340,000) -- --
Repayment of capital lease obligations and other liabilities (573,000) (275,000) --
----------- ----------- -----------
Net cash provided by financing activities 4,633,000 21,000 --
Effect of exchange rate changes on cash 6,000 -- --
----------- ----------- -----------
Net increase (decrease) in cash and cash equivalents (209,000) 178,000 450,000
Cash and cash equivalents - beginning of year 936,000 758,000 308,000
----------- ----------- -----------
Cash and cash equivalents - end of year $ 727,000 $ 936,000 $ 758,000
=========== =========== ===========
Supplemental schedule of noncash operating and financing activities:
Inventory purchase with deferred payment terms $ 250,000 -- --
Common stock issued as incentive to purchase notes $ 156,000 -- --
</TABLE>
See accompanying notes.
13
<PAGE>
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
Additional Accumulated Total
Preferred Common paid-in Accumulated translation shareholders'
Stock Stock capital deficit adjustments equity
--------- ---------- ----------- ------------ ------------- -------------
<S> <C> <C> <C> <C> <C> <C>
Balances, January 1, 1993
(4,982,670 common shares) $2,491,000 $12,863,000 $(11,087,000) $ 4,267,000
Net loss (1,485,000) (1,485,000)
---------- ----------- ------------ -----------
Balances, December 31, 1993
(4,982,670 common shares) 2,491,000 12,863,000 (12,572,000) 2,782,000
Issuance of 40,000 Series A
preferred and 4,340,092
common shares in
connection with 1994
business combinations
(Note 3) $ -- 2,170,000 7,367,000 9,537,000
Accumulated
translation adjustments $(53,000) (53,000)
Net loss (5,567,000) (5,567,000)
------ ---------- ----------- ------------ -------- -----------
Balances, December 31, 1994
(40,000 Series A preferred
shares and 9,322,762
common shares) -- 4,661,000 20,230,000 (18,139,000) (53,000) 6,699,000
Issuance of 93,300 common
shares in connection with
short-term notes 47,000 109,000 156,000
Sale of 1,227625 common
shares 614,000 1,089,000 1,703,000
Conversion of 40,000
Series A preferred shares
to 40,000 common shares -- 20,000 (20,000) --
Issuance of 1,440,736 common
shares in connection with
1995 business combination
(Note 3) 720,000 2,633,000 3,353,000
Issuance of 642,583 Series B
preferred shares (Note 3) 6,000 1,169,000 1,175,000
Accumulated translation
adjustments 110,000 110,000
Net loss (8,892,000) (8,892,000)
------ ---------- ----------- ------------ -------- -----------
Balances, December 31, 1995
(642,583 Series B preferred
shares and 12,124,423
common shares) $6,000 $6,062,000 $25,210,000 $(27,031,000) $ 57,000 $ 4,304,000
====== ========== =========== ============ ======== ===========
</TABLE>
See accompanying notes.
14
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31,
1995, 1994 AND 1993
1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
OXIS International, Inc. (the Company) develops, manufactures and markets
selected therapeutic and diagnostic products. The Company's research and
development efforts are concentrated principally in the development of products
to diagnose, treat and prevent diseases associated with free radicals and
reactive oxygen species. Headquartered in Portland, Oregon, the Company
operates research and development facilities in Malvern, Pennsylvania, and near
Paris, France.
The Company has historically licensed and sold pharmaceutical forms of
superoxide dismutase (SOD) for human and veterinary use. In 1994, with the
acquisitions of businesses as described in Note 3, the Company began selling
therapeutic drug monitoring assays and research assays to measure markers of
oxidative stress, and began performing custom assay development.
Therapeutic drug monitoring assays are manufactured by the Company in the United
States and are sold to hospital clinical laboratories and reference laboratories
by an in-house sales force and a network of distributors both within and outside
the United States. Assays to measure markers of oxidative stress are
manufactured by the Company in France and are sold to distributors for resale to
researchers, primarily in Europe, the United States and Japan.
These financial statement have been prepared on a going concern basis which
contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. The Company has incurred losses in each of the
last three years, and at December 31, 1995, the Company's current liabilities
exceeded its current assets by $1,469,000. These factors, among others, may
indicate that the Company may be unable to continue as a going concern for a
reasonable period of time. These financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that may be necessary
should the Company be unable to continue as a going concern. The Company's
continuation as a going concern is contingent upon its ability to obtain
additional financing, and to generate revenue and cash flow to meet its
obligations on a timely basis.
During the first quarter of 1996 the Company is seeking additional capital
through a private placement of up to $4,000,000 of its Series C Preferred Stock.
On March 4, 1996, the Company had closed the sale of 587,053 shares of Series C
Preferred Stock for $763,000. If the Company is able to sell the entire
$4,000,000 of Series C Preferred Stock, it still expects that additional capital
will be required during 1996 to continue operating in accordance with its
current plans. If the Company is unable to raise additional capital it intends
to curtail its operations through the reduction of personnel and facility costs
and by reducing its research and development efforts. If the Company were to be
unable to sufficiently curtail its costs in such a situation, it might be forced
to seek protection of the courts through reorganization, bankruptcy or
insolvency proceedings.
2. SIGNIFICANT ACCOUNTING POLICIES
Principles of consolidation - The accompanying balance sheets include the
accounts of the Company as well as its subsidiaries. The results of operations
of the Company's French subsidiary since its purchase by the Company on
September 7, 1994, are included in the accompanying statements of operations and
cash flows. The functional currency of the Company's French subsidiary is the
French franc. The French subsidiary's assets and liabilities are translated at
the exchange rate at the end of the year, and its statement of operations is
translated at the average exchange rates during the period for which its
revenues and expenses are included in the consolidated statement of operations.
Gains or losses resulting from foreign currency translation are accumulated as a
separate component of shareholders' equity. All significant
15
<PAGE>
intercompany balances and transactions are eliminated in consolidation.
Cash equivalents consist of money market accounts with commercial banks.
Inventories are stated at the lower of cost or market. Cost has been determined
by using the first-in, first-out and specific identification methods.
Inventories at December 31, 1995 and 1994, consisted of the following:
<TABLE>
<CAPTION>
1995 1994
-------- --------
<S> <C> <C>
Raw materials $173,000 $179,000
Work in process 354,000 357,000
Finished goods 426,000 137,000
-------- --------
Total $953,000 $673,000
======== ========
</TABLE>
Property and equipment is stated at cost, or, in the case of property and
equipment acquired in transactions accounted for by the purchase method, at the
estimated fair market value at the date of the acquisition (which is then
considered to be the Company's cost). Depreciation of equipment is computed
using the straight-line method over estimated useful lives of three to ten
years. Leasehold improvements are amortized over the shorter of five years or
the remaining lease term. Assets acquired under capital leases are being
amortized over estimated useful lives of four to ten years.
Property and equipment at December 31, 1995 and 1994, consisted of the
following:
<TABLE>
<CAPTION>
1995 1994
----------- -----------
<S> <C> <C>
Furniture and office
equipment $ 346,000 $ 319,000
Laboratory and
manufacturing equipment 707,000 649,000
Automobile 15,000 15,000
Leasehold improvements 806,000 710,000
---------- ----------
Property and equipment,
at cost 1,874,000 1,693,000
Accumulated depreciation
and amortization (782,000) (395,000)
---------- ----------
Property and equipment, net $1,092,000 $1,298,000
========== ==========
</TABLE>
Technology - Technology for developed products and custom assays, which was
acquired in the 1994 business combinations described in Note 3, is being
amortized over estimated useful lives of seven to ten years. Accumulated
amortization of technology for developed products and custom assays was $973,000
as of December 31, 1995 and $239,000 as of December 31, 1994. The Company
periodically reviews net cash flows from sales of products and projections of
net cash flows from sales of products on an undiscounted basis to assess
recovery of intangible assets.
Revenue recognition - The Company normally recognizes product sales upon
shipment of the product to the customer. Product sales may be recorded on the
scheduled shipment date if the customer has delayed shipment, but has agreed to
accept title to the product and has paid for the product. Sales from custom
assay development contracts is recognized as the work is performed. Revenue
derived from royalties pursuant to license agreements is recognized after sales
information is reported by licensees.
Income taxes - The Company accounts for income taxes under statement of
Financial Accounting Standards No. 109, "Accounting for Income Taxes" which
requires deferred income taxes be provided to reflect temporary differences
between financial and tax bases of assets and liabilities using presently
enacted tax rates and laws.
Net loss per share - Net loss per share is computed based upon the average
number of common shares outstanding and, if dilutive, the incremental shares
issuable upon the assumed exercise of stock options or warrants and the assumed
conversion of convertible debentures and preferred stock.
Use of estimates - The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported
16
<PAGE>
amounts of sales and expenses during the reporting period. Actual results could
differ from those estimates.
Fair value of financial instruments - The carrying amount reported in the
balance sheet for cash and cash equivalents, certificates of deposit, accounts
receivable, notes payable, customer deposits and accrued liabilities
approximates fair value due to the short-term nature of the accounts. The
carrying amount reported in the balance sheet for 8% convertible subordinated
debentures approximates fair value because the terms of the debentures were
determined and the debentures were sold shortly before the end of 1995.
3. BUSINESS COMBINATIONS
On September 7, 1994, the Company acquired Bioxytech S.A., a French company, and
International BioClinical, Inc. (IBC), an Oregon corporation. The name of
Bioxytech S.A. was subsequently changed to OXIS International S.A. (OXIS S.A.)
OXIS S.A. was acquired through an exchange of shares that resulted in the
Company owning in excess of 99% of the outstanding stock of OXIS S.A., which
thus became a subsidiary of the Company. IBC was acquired through a merger with
and into the Company, which (1) terminated the separate existence of IBC by
merging it into the Company, and (2) resulted in the conversion of the
outstanding stock of IBC into stock of the Company. Two of the Company's
directors were also directors and major shareholders of IBC.
In exchange for the Bioxytech S.A. shares, the Company issued a total of
2,341,599 shares of the Company's common stock and 40,000 shares of the
Company's non-voting preferred stock (which have subsequently been converted
into 40,000 shares of common stock). In addition, the Bioxytech S.A.
shareholders may receive up to 107,670 shares of the Company's capital stock if
they meet certain participation levels in a contemplated private placement of
equity securities of the Company.
The merger of IBC with and into the Company resulted in the conversion of IBC's
common stock into 1,998,493 shares of the Company's common stock.
The acquisitions of OXIS S.A. and IBC have been accounted for as purchases and,
accordingly, the acquired assets and liabilities were recorded at their
estimated fair market values as of the date of acquisition. The aggregate
purchase price of $9,811,000 (4,380,092 shares issued times the average per
share closing price of the Company's common stock for the five days ended
September 8, 1994, discounted 30% for certain trading restrictions and less
costs of $274,000 directly attributable to issuance of stock in connection with
the acquisitions) plus direct costs for the acquisitions of $881,000 have been
allocated to the assets and liabilities acquired. The Company also issued
options to purchase 214,700 shares of the Company's common stock in connection
with the acquisitions. No value was assigned to these options because the
exercise price of the options was in excess of the market value of the common
stock.
17
<PAGE>
The total cost of the acquisitions of OXIS S.A. and IBC has been allocated to
the assets acquired and liabilities assumed as follows:
<TABLE>
<CAPTION>
OXIS S.A. IBC Total
------------ ------------ ------------
<S> <C> <C> <C>
Cash $ 150,000 $ 123,000 $ 273,000
Other assets 369,000 611,000 980,000
Property, equipment and capitalized leases 2,434,000 294,000 2,728,000
Technology for developed products and
custom assay development capabilities 1,503,000 3,995,000 5,498,000
Technology for in-process products 3,368,000 307,000 3,675,000
Less liabilities assumed (2,011,000) (451,000) (2,462,000)
----------- ---------- -----------
Total acquisition cost $ 5,813,000 $4,879,000 $10,692,000
=========== ========== ===========
</TABLE>
------------------------------------------------------------
The Company's consolidated results of operations include the operating results
of the acquired companies since the acquisitions.
Approximately $3,675,000 ($.58 per share) of the total purchase price
represented technology relating to research and development projects that were
in process by the acquired companies that had no alternative future use other
than the completion of these projects. In accordance with generally accepted
accounting principles, these costs have been charged to operations immediately
upon completion of the acquisitions.
The following table summarizes the unaudited pro forma combined results of
operations for the years ended December 31, 1994 and 1993 as if the acquisitions
had occurred at the beginning of the years presented:
<TABLE>
<CAPTION>
1994 1993
------------ ------------
<S> <C> <C>
Total revenues $ 5,809,000 $ 6,736,000
Net loss $(4,742,000) $(5,207,000)
Net loss per share
(based on 9,322,762
shares outstanding) $ (.51) $ (.56)
</TABLE>
The above table includes, on an unaudited pro forma basis, the Company's
financial information for the years ended December 31, 1994 and 1993, combined
with the financial information of OXIS S.A. and IBC for the same twelve-month
periods. The above table excludes the one-time $3,675,000 charge for purchased
in-process technology arising from the acquisitions. Pro forma results for the
year ended December 31, 1993 include non-recurring costs of $1,531,000 in
connection with a control contest.
The unaudited pro forma combined results of operations are presented for
illustrative purposes only and are not necessarily indicative of the operating
results that would have occurred had the acquisitions been consummated at the
beginning of the periods presented, nor are they necessarily indicative of
future operating results.
On July 19, 1995, the Company consummated the acquisition of Therox
Pharmaceuticals, Inc. (Therox) pursuant to a transaction wherein Therox was
merged with and into a wholly-owned subsidiary of the Company. Therox was a
Philadelphia-based start-up company focused on the development of therapeutics
to treat diseases associated with damage from free radicals. The Company issued
1,440,736 shares of its common stock to Therox stockholders in exchange for all
of the Therox capital stock. In addition, the acquisition agreement provides
for payment of up to $2,000,000 by the Company to the Therox stockholders based
on the successful commercialization of the Therox technologies.
The acquisition of Therox has been recorded as a purchase and, accordingly, the
acquired assets and liabilities were recorded at their estimated fair values as
of the date of
18
<PAGE>
acquisition. The aggregate purchase price of $3,353,000 (1,440,736 shares
issued times the average per share closing price of the Company's common stock
for the five days ended July 20, 1995, discounted 30% for certain trading
restrictions) has been allocated to the assets and liabilities acquired.
The cost of the acquisition of Therox has been allocated to the assets acquired
and liabilities assumed as follows:
<TABLE>
<S> <C>
Cash $ 143,000
Equipment 16,000
Technology for in-process
products 3,329,000
Other assets 23,000
Less liabilities assumed (158,000)
----------
Acquisition cost $3,353,000
==========
</TABLE>
The Company's consolidated results of operations include the operating results
of the acquired company since the acquisition.
Approximately $3,329,000 of the purchase price represented technology related to
research and development projects that are in process and that has no
alternative future use other than the completion of these projects.
Accordingly, these costs have been charged to operations immediately upon
completion of the acquisition.
The following table presents the unaudited pro forma combined results of
operations for the years ended December 31, 1995 and 1994 as if the acquisition
had occurred at the beginning of the periods presented:
<TABLE>
<CAPTION>
1995 1994
------------ ------------
<S> <C> <C>
Total revenues $ 5,136,000 $ 3,470,000
Net loss $(5,990,000) $(6,088,000)
Net loss per share
(based on 12,124,423
shares outstanding) $ (.49) $ (.50)
</TABLE>
The above table includes, on an unaudited pro forma basis, the Company's
financial information for the years ended December 31, 1995 and 1994, combined
with the financial information of Therox for the same periods. The above table
excludes the one-time $3,329,000 charge for purchased in-process technology
arising from the 1995 acquisition, but includes non-recurring costs of
$3,675,000 for purchased in-process technology from the Company's September 1994
business acquisitions.
The unaudited pro forma combined results of operations are presented for
illustrative purposes only and are not necessarily indicative of the operating
results that would have occurred had the acquisition been consummated at the
beginning of the periods presented, nor are they necessarily indicative of
future operating results.
Simultaneously with the Therox acquisition, a Series B Preferred Stock Purchase
Agreement was entered into between the Company and two venture capital firms
(S.R. One, Limited and Brantley Venture Partners II, L.P.) which were major
stockholders of Therox. Pursuant to this agreement, the Company sold 642,583
shares of its Series B Preferred Stock for an aggregate price of $1,500,000.
Costs of approximately $325,000 directly attributable to the issuance of the
Series B Preferred Stock and the common stock issued in the Therox acquisition
have been recorded as a reduction in the proceeds from the issuance of the
shares.
19
<PAGE>
4. NOTES PAYABLE
Notes payable at December 31, 1995 consisted of the following:
<TABLE>
<S> <C>
8% notes payable to certain share-
holders who are former Bioxytech
S.A. shareholders, due February 5,
1996, secured by assets relating to
certain of the Company's diagnostic
products $ 766,000
Note payable to Sanofi S.A., due
May 4, 1996, interest at prime plus
2% (10-1/2% as of December 31,
1995), secured by all of the Com-
pany's assets 600,000
Liability, without interest, under
inventory purchase agreement,
due May 1997 or earlier if 75% of
the related inventory is sold 250,000
----------
$1,616,000
==========
</TABLE>
The shareholders who hold the 8% notes have commitments to invest an amount at
least equal to the note balances in stock of the Company. During March 1996 the
Company is negotiating with these shareholders terms for converting these notes
to stock of the Company.
5. CAPITALIZED LEASES
The Company's French subsidiary leases certain equipment, furniture and fixtures
under capital leases. The future minimum lease payments on these capital leases
as of December 31, 1995, were as follows:
<TABLE>
<S> <C>
Year ending December 31:
1996 $309,000
1997 47,000
--------
Total minimum capital lease
obligations 356,000
Less amounts representing interest 26,000
--------
Present value of net minimum
obligation 330,000
Less amount due within one year 283,000
--------
Long term obligation under
capital leases $ 47,000
========
</TABLE>
Leased assets, which consist principally of laboratory and office equipment, are
reported in the December 31, 1995, balance sheet at $1,418,000 less accumulated
amortization of $220,000.
6. 8% CONVERTIBLE SUBORDINATED DEBENTURES
In November and December 1995, the Company completed a private placement
pursuant to which $1,255,000 of its 8% Convertible Subordinated Debentures were
issued. The debentures are unsecured and are subordinated to other obligations
of the Company up to an aggregate of $3,000,000. The Debentures are due
December 31, 1997; interest is payable semiannually on June 30 and December 31.
The debentures are convertible into shares of the Company's common stock at the
option of the holders. Any time after six months following closing of the
private placement, the Company may require conversion of the debentures. The
debentures are convertible at a conversion price of $1.25 per common share.
However, the conversion price shall be reduced to $.65 per share if the closing
price of the Company's common stock is less than $.65 for fifteen consecutive
trading days. In such case, the debentures could be converted into a maximum of
1,930,769 shares of common stock.
7. SHAREHOLDERS' EQUITY
Preferred Stock - Terms of the preferred stock are to be fixed by the Board of
Directors at such time as the preferred stock is issued. The 40,000 shares of
Series A Preferred Stock issued during 1994 were nonvoting and were converted to
common stock on a one share for one share basis during 1995. The 642,583 shares
of Series B Preferred Stock are convertible into common stock on a one-for-one
basis and have the same voting rights as the common stock. The Series B
Preferred Stock has certain preferential rights with respect to liquidation and
dividends.
20
<PAGE>
In February and March 1996, the Company has issued 587,053 shares of Series C
Preferred Stock. Each share of Series C Preferred Stock is initially
convertible into one share of the Company's common stock at the option of the
holder at any time. After six months following the closing of the sales of
Series C preferred Stock, the conversion ratio may be adjusted under certain
circumstances, and after eight months following the closing, the Company may
have the right to automatically convert the Series C Preferred Stock into common
stock under certain circumstances. The Series C Preferred Stock has the same
voting rights as the Company's common stock based on the number of shares into
which the Series C Preferred Stock is convertible, subject to adjustment in
certain circumstances.
Stock Warrants - In prior years, the Company issued warrants to purchase shares
of common stock to certain officers and key employees (none of whom any longer
hold a position with the Company) and to former directors. These warrants are
exercisable at $2.875 per share and expire through 1999. At December 31, 1995
and 1994, warrants to purchase 1,012,500 shares were exercisable. No warrants
were exercised during the years ended 1993, 1994 or 1995.
In connection with the issuance of common stock in May 1995, the Company issued
to its placement agent a warrant to purchase 122,763 shares of common stock at
$2.89 per share. This warrant was immediately exercisable upon issuance and
remained outstanding at December 31, 1995.
Warrants to purchase 200,800 common shares at $2.00 per share were issued to
purchasers of the Company's 8% Convertible Subordinated Debentures and remained
outstanding at December 31, 1995. The number of common shares which may be
purchased pursuant to these warrants may be increased in the event that the
number of common shares into which the related debentures may be converted is
increased. The maximum number of common shares to which these warrants might
entitle the holders is 386,154.
Also in connection with the issuance of its 8% Convertible Subordinated
Debentures, the Company issued to its placement agent warrants to purchase
100,400 shares of common stock at $1.375 per share. These warrants were
immediately exercisable upon issuance and remained outstanding at December 31,
1995.
Stock Options - In September 1994, the Company's shareholders approved the 1994
Stock Incentive Plan and the reservation of 400,000 shares of the Company's
common stock for issuance thereunder. In August 1995, the shareholders approved
an amendment to the plan increasing the shares reserved for issuance thereunder
to 1,200,000. The plan permits granting stock options to acquire shares of the
Company's common stock, awarding stock bonuses of the Company's common stock,
and granting stock appreciation rights.
21
<PAGE>
Options granted and outstanding under the plan are summarized as follows:
<TABLE>
<CAPTION>
1995 1994
------ ------
Shares Price Shares Price
------- ------------- ------ -------------
<S> <C> <C> <C> <C>
Outstanding at beginning of year 90,000 $3.13 - $3.50 --
Granted 317,900 $2.25 - $3.50 90,000 $3.13 - $3.50
Forfeitures (25,000) $2.25 --
------- ------
Outstanding at end of year 382,900 $2.25 - $3.50 90,000 $3.13 - $3.50
======= ======
Exercisable at end of year 219,294 $2.25 - $3.50 75,000 $3.50
======= ======
</TABLE>
------------------------------------------------------------
8. INCOME TAXES
Income Tax Provision - Income tax provisions were not necessary in 1995, 1994
and 1993 due to net losses.
Deferred Taxes - Deferred taxes reflect the net tax effects of (a) temporary
differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and (b)
operating losses and tax credit carryforwards.
The tax effects of significant items comprising the Company's deferred taxes as
of December 31 were as follows:
<TABLE>
<CAPTION>
1995 1994
------------ ------------
<S> <C> <C>
United States taxes:
Deferred tax assets:
Federal net operating loss carryforward
and capitalized research and development
expenses $ 4,829,000 $ 2,110,000
Federal R&D tax credit carryforward 495,000 465,000
State net operating loss carryforward and capitalized
research and development expenses 125,000 372,000
Deferred tax liabilities - book basis in excess
of noncurrent assets acquired in the
acquisition of IBC (1,338,000) (1,575,000)
----------- -----------
Net deferred tax assets 4,111,000 1,372,000
Valuation allowance (4,111,000) (1,372,000)
----------- -----------
Net deferred taxes $ -- $ --
=========== ===========
French taxes:
Deferred tax assets:
Net operating loss carryforward $ 5,721,000 $ 5,286,000
Impact of temporary differences (225,000) 453,000
----------- -----------
Total 5,496,000 5,739,000
Valuation allowance (5,496,000) (5,739,000)
----------- -----------
Net deferred taxes $ -- $ --
=========== ===========
</TABLE>
22
<PAGE>
Temporary differences for French taxes result primarily from leases treated as
operating leases for French tax reporting and as capital leases in the
consolidated financial statements.
The tax benefits ($5,136,000) of the net operating losses of $15,410,000 which
existed at the date of acquisition (September 7, 1994) of the French subsidiary
will be recorded as a reduction of the net unamortized balance of property,
equipment, capitalized lease assets and intangible assets of $3,147,000 when and
if realized, and the remaining benefit will be recorded as a reduction of income
tax expense.
Statement of Financial Accounting Standards No. 109 requires that the tax
benefit of net operating losses, temporary differences and credit carryforwards
be recorded as an asset to the extent that management assesses that realization
is "more likely than not." Realization of the future tax benefits is dependent
on the Company's ability to generate sufficient taxable income within the
carryforward period. Because of the Company's recent history of operating
losses, management has provided a valuation allowance for its net deferred tax
assets.
Tax Carryforwards - At December 31, 1995, the Company had net operating loss
carryforwards of approximately $5,120,000 to reduce United States federal
taxable income in future years, and research and development tax credit
carryforwards of $495,000 to reduce United States federal taxes in future years.
In addition, the Company's French subsidiary had operating loss carryforwards of
$17,165,000 (84,183,000 French francs) to reduce French taxable income in future
years. These carryforwards expire as follows:
<TABLE>
<CAPTION>
United States R&D tax French
net operating credit operating loss
Year of expiration loss carryforward carryforward carryforward
- ------------------ ----------------- -------------- --------------
<S> <C> <C> <C>
1996 $1,219,000 $ 1,655,000
1997 2,670,000 1,270,000
1998 208,000 1,312,000
1999 111,000 233,000
2000 -- -- --
2001-2010 912,000 $ 495,000 --
No expiration -- -- 12,695,000
---------- ---------- -----------
$5,120,000 $ 495,000 $17,165,000
========== ========== ===========
</TABLE>
Utilization of the United States tax carryforwards is subject to certain
restrictions in the event of a significant change (as defined in Internal
Revenue Service guidelines) in ownership of the Company.
------------------------------------------------------------
23
<PAGE>
9. MAJOR CUSTOMERS AND CONCENTRATION OF CREDIT RISK
One domestic customer and three foreign licensees have each accounted for
significant portions of the Company's revenues during the past three years. The
percentages of total revenues derived from sales to, and royalties from, these
major customers are as follows:
<TABLE>
<CAPTION>
1995 1994 1993
----- ----- -----
<S> <C> <C> <C>
Domestic customer 18% 35% 50%
Spanish licensee 16% 18% 8%
German licensee 2% 9% 23%
Italian licensee -- 2% 7%
</TABLE>
The Company's domestic customer to whom sales of bovine superoxide dismutase
(bSOD) accounted for 18%, 35% and 50% of the Company's revenues in 1995, 1994
and 1993, respectively, announced in the fourth quarter of 1995 that the
clinical trial in which it was using bSOD purchased from the Company failed to
show the desired results. Therefore, sales of bSOD to this customer are not
expected to continue.
The Company limits its foreign exchange risk by buying and selling bulk bSOD in
a single currency, the Dutch guilder. The Company maintains a bank account in
The Netherlands for receipt and disbursement of Dutch guilders and had the
equivalent of $81,000 and $659,000 in that account at December 31, 1995 and
1994, respectively. Foreign currency transaction gains and losses were not
material.
10. GEOGRAPHIC AREA INFORMATION
The Company operates in a single industry segment: the development, manufacture
and marketing of therapeutic and diagnostic products. The Company's foreign
operations consist of research and development and manufacturing facilities and
certain marketing activities conducted by the Company's subsidiary in France.
Sales and costs associated with bSOD manufactured in the Netherlands are
considered to be United States operations, since the contract to manufacture
bSOD and all related sales activities are administered in the United States.
Similarly, royalties from foreign customers that relate to bSOD-based products
are considered to be export sales from the United States, since the product was
developed in the United States.
------------------------------------------------------------
Sales, operating income and identifiable assets, classified by the major
geographic areas in which the Company operates, are as follows:
<TABLE>
<CAPTION>
1995 1994 1993
------------ ------------ -----------
<S> <C> <C> <C>
Revenues from unaffiliated customers:
United States $ 2,686,000 $ 2,053,000 $ 1,887,000
Export sales from the U.S. 1,878,000 1,257,000 1,157,000
France 572,000 160,000 --
----------- ----------- -----------
Total $ 5,136,000 $ 3,470,000 $ 3,044,000
=========== =========== ===========
Operating income (loss):
United States $(5,653,000) $(1,410,000) $(1,638,000)
France (3,110,000) (4,191,000) --
----------- ----------- -----------
Total $(8,763,000) $(5,601,000) $(1,638,000)
=========== =========== ===========
Identifiable assets:
United States $ 7,824,000 $ 9,587,000 $ 3,124,000
France 3,866,000 2,570,000 --
Eliminations (1,820,000) (963,000) --
----------- ----------- -----------
Total $ 9,870,000 $11,194,000 $ 3,124,000
=========== =========== ===========
</TABLE>
24
<PAGE>
11. LEASE COMMITMENTS
The Company leases its facilities in Oregon under an operating lease that
expires in 1997, and leases its facilities in Pennsylvania and France under
operating leases that expire in 1998. Future lease payments are scheduled as
follows:
<TABLE>
<S> <C>
1996 $480,000
1997 436,000
1998 245,000
</TABLE>
Rental expense included in the accompanying statements of operations was
$492,000 in 1995, $193,000 in 1994 and $75,000 in 1993.
12. EUROPEAN REGULATORY DEVELOPMENTS
The European market for the Company's bovine bSOD was adversely impacted by a
series of regulatory developments in 1994.
The Italian Health Ministry withdrew the marketing authorization of all
pharmaceutical products composed of orgotein, including Oxinorm (produced from
the Company's product). As indicated in Note 9, the Company's revenues from its
Italian licensee have ceased, and the Company does not anticipate additional
sales or royalties from Oxinorm in Italy. During 1995, SmithKline Beecham
Farmaceutici S.p.A., the Company's licensee in Italy, sold its remaining bulk
Oxinorm inventory to the Company.
During 1994 the Company was also notified that the governments of Austria and
Germany had asked Grunenthal, the Company's licensee for those countries, to
withdraw its Peroxinorm brand of orgotein from the Austrian and German markets.
Grunenthal has also discontinued distributing Peroxinorm in several other
countries where sales were dependent upon the German registration. As a result,
the Company anticipates that royalties from Grunenthal for the foreseeable
future will be substantially less than in previous years.
Because of the action of regulatory authorities in other European countries, the
Company's licensee for Spain has had informal discussions with Spanish
regulatory authorities regarding the Company's bSOD product. Although no action
has been taken by those authorities with regard to the Company's product, future
sales in Spain may be affected by either regulatory action in Spain, or safety
concerns stemming from such actions in other countries.
13. CONTROL CONTEST EXPENSES
In 1993, the Company incurred expenses of $1,531,000 ($.31 per share) in
connection with a contest for management control of the Company. Costs incurred
by current officers and directors were advanced by IBC. The President and the
Chairman of the Company were major shareholders of IBC. Reimbursement of IBC
for such expenses was approved at the Company's 1993 annual shareholders'
meeting.
14. 401(k) SAVINGS PLAN
The Company has a 401(k) saving plan (the Plan) which covers all United States
employees who meet certain minimum age and service requirements. The Company's
matching contribution to the Plan for each year is 100% of the first $1,000 of
each employee's salary deferral and 33-1/3% of the next $3,000 of salary
deferral. The Company's contributions have not been material.
25
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Board of Directors of
OXIS International, Inc.:
We have audited the accompanying consolidated balance sheets of OXIS
International, Inc. and subsidiaries as of December 31, 1995 and 1994, and the
related consolidated statements of operations, shareholders' equity and cash
flows for each of the three years in the period ended December 31, 1995. These
financial statements are the responsibility of the management of OXIS
International, Inc. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the consolidated financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.
In our opinion, such consolidated financial statements present fairly, in all
material respects, the financial position of OXIS International, Inc. and
subsidiaries at December 31, 1995 and 1994, and the results of their operations
and their cash flows for each of the three years in the period ended December
31, 1995, in conformity with generally accepted accounting principles.
The accompanying financial statements for the year ended December 31, 1995, have
been prepared assuming that the Company will continue as a going concern. The
Company is engaged in developing, manufacturing and marketing selected
therapeutic and diagnostic products. As discussed in Note 1 to the financial
statements, the Company has incurred losses in each of the last three years, and
at December 31, 1995, the Company's current liabilities exceeded its current
assets by $1,469,000, raising substantial doubt about its ability to continue as
a going concern. Management's plans concerning these matters are also described
in Note 1. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
DELOITTE & TOUCHE LLP
March 7, 1996
Portland, Oregon
26
<PAGE>
Scientific Advisory Board
Ronald T. Borchart, Ph.D.
Solon E. Summerfield Professor
Chairman, Department of Pharmaceutical Chemistry
University of Kansas
Lawrence, Kansas
Bruce Freeman, Ph.D.
Professor, Department of Anesthesiology, Biochemistry and Molecular Genetics
Professor, Department of Pediatrics
University of Alabama
Birmingham, Alabama
Joe M. McCord, Ph.D.
Professor of Medicine
Professor of Biochemistry, Biophysics and Molecular Genetics
Professor of Microbiology and Immunology
University of Colorado
Head, Division of Biochemistry and Molecular Biology, Webb-Waring Institute for
Biomedical Research
Denver, Colorado
John E. Repine, Ph.D.
James J. Waring Professor of Medicine, University of Colorado Health Sciences
Center
President and Director, Webb-Waring Institute for Biomedical Research
Denver, Colorado
(ad hoc)
Gerald D. Mayer, Ph.D.
Director, OXIS International, Inc.
Cincinnati, Ohio
Management
Anna D. Barker, Ph.D.
President and Chief Executive Officer
Charles A. Martin
Vice President of Diagnostics Marketing and Sales
Paul A. Mueggler, Ph.D.
Vice President of Diagnostic Technical Operations
Jon S. Pitcher
Vice President of Finance and Administration
Chief Financial Officer
Timothy C. Rodell, M.D.
Chief Operating Officer
Lynda M. Taylor
Vice President of Quality Assurance and Regulatory Affairs
Jean-Claude Yadan, Ph.D.
Scientific Director, OXIS International SA
John Ziemniak, Ph.D.
Vice President of Pharmaceutical Development
Board of Directors
Anna D. Barker, Ph.D.
President and Chief Executive Officer
OXIS International, Inc.
Portland, Oregon
Timothy Biro
General Partner
Brantley Venture Partners II, LLP
Brantley Venture Partners III, LLP
Cleveland, Ohio
Stuart S. Lang
Managing Member
The Lang Group
Portland, Oregon
Gerald Mayer, Ph.D.
Retired
Cincinnati, Ohio
James D. McCamant
President
Piedmont Venture Group
Berkeley, California
David Needham, Ph.D.
Consultant
Alta Berkeley Associates
London, United Kingdom
Ray R. Rogers
Chairman of the Board
OXIS International, Inc.
Portland, Oregon
A.R. Sitaraman
President and Chief Executive Officer
Sitrex International, Inc.
Glendale, California
27
<PAGE>
Corporate Headquarters
OXIS International, Inc.
6040 N. Cutter Circle
Suite 317
Portland, OR 97217-3935
503-283-3911
Annual Report Form 10-K
A copy of the Company's Annual Report on Form 10-K as filed with the Securities
and Exchange Commission is available without charge on request to:
Investor Relations
OXIS International, Inc.
6040 N. Cutter Circle
Suite 317
Portland, OR 97217-3935
503-283-3911
Annual Meeting
The Annual Meeting of Stockholders will be held at 2:00 PM on Thursday, June 13,
1996 at The Vintage Plaza Hotel, 627 SW Washington, Portland, Oregon
Transfer Agent and Registrar
Boston EquiServe
P.O. Box 644
Boston, MA 02102
1-800-442-2001
Corporate Counsel
Jackson, Tufts, Cole & Black
San Jose, California
------------------------------------------------------------
OXIS International, Inc. has an estimated 7,000 shareholders, including
approximately 2,500 shareholders who have shares in the names of their
stockbrokers. The Company utilizes its assets to develop its business and,
consequently, has never paid a dividend and does not expect to pay dividends in
the foreseeable future.
OXIS' common stock is traded on the NASDAQ National Market System using the
symbol OXIS. Recent quarterly prices of the Company's common stock are as
follows:
<TABLE>
<CAPTION>
1995 1994
------------------------------- -----------------------------
4th 3rd 2nd 1st 4th 3rd 2nd 1st
<S> <C> <C> <C> <C> <C> <C> <C> <C>
High 2 13/16 3 1/2 4 1/2 2 7/8 3 1/8 3 1/2 4 4 3/8
Low 1 1/8 2 1/4 1 3/4 1 5/8 1 3/8 2 1/2 2 5/8 3 1/8
</TABLE>
28
<PAGE>
OXIS INTERNATIONAL, INC.
PROXY SOLICITED BY AND ON BEHALF OF THE BOARD OF DIRECTORS
P
R The undersigned hereby appoints Anna D. Barker and Ray R. Rogers,
and each of them, as Proxies, each with the power to appoint his or her
O substitute, to represent and to vote, as designated on the reverse side,
all the shares of Common and Preferred Stock of OXIS International, Inc.
X held of record by, or otherwise entitled to be voted by, the undersigned
on April 19, 1996 at the 1996 Annual Meeting of Stockholders of OXIS
Y International, Inc., to be held on June 13, 1996 and any adjournment or
postponement thereof.
SEE REVERSE
CONTINUED AND TO BE SIGNED ON REVERSE SIDE SIDE
<PAGE>
[X] Please mark
votes as in
this example.
This proxy, when properly executed, will be voted in the manner directed herein
by the undersigned stockholder. If no directions are indicated, the Proxies will
vote FOR Proposals 1, 2 and 3.
1. ELECTION OF DIRECTORS
Nominees: Anna D. Barker, Ph.D.; Timothy G. Biro; Stuart S. Lang; James D.
McCamant; Gerald D. Mayer, Ph.D.; David A. Needham, Ph.D.; Ray R. Rogers; A.R.
Sitaraman.
FOR WITHHELD
[_] [_]
[_]_________________________________________
For all nominees, except as noted above
2. To approve the proposal to amend the Company's Restated Certificate of
Incorporation to increase the authorized number of Common Shares from
25,000,000 to 40,000,000 and to increase the authorized number of Preferred
Shares from 5,000,000 to 15,000,000.
FOR AGAINST ABSTAIN
[_] [_] [_]
3. To approve the proposal to amend the 1994 Stock Incentive Plan increasing
the number of shares issuable thereunder to 2,200,000 shares of the
Company's Common Stock.
FOR AGAINST ABSTAIN
[_] [_] [_]
4. OTHER MATTERS
The Proxies are authorized to vote in their discretion, upon such other
matters as may properly come before the meeting, and any adjournment or
postponement thereof.
MARK HERE [_] If stock is held jointly, signatures
FOR ADDRESS should include both names, if stock is
CHANGE AND held by executors, administrators,
NOTE BELOW trustees, guardians and others signing in
a representative capacity, please give
full title. If stock is held by a
corporation, please sign in full
corporate name and give name and title of
authorized officer. If stock is held by a
partnership, please sign in partnership
name by authorized person.
Signature: _________________ Date: ______
Signature: _________________ Date: ______
PLEASE MARK, DATE, SIGN AND MAIL THIS
PROXY PROMPTLY IN THE RETURN ENVELOPE
ENCLOSED.
